65 results on '"Orazi S"'
Search Results
2. PROGNOSTIC ROLE OF C-REACTIVE PROTEIN IN POST-MI ICD PATIENTS: RESULTS OF THE CAMI GUIDE STUDY: 5.7
- Author
-
Bellocci, F., Giubilato, G., Landolina, M., Crea, F., Orazi, S., Sassara, M., Castro, A., Massa, R., Kheir, A., Zaccone, G., Achilli, F., Accardi, F., and Biasucci, L. M.
- Published
- 2009
3. PREDICTORS OF CHRONOTROPIC INCOMPETENCE IN DUAL SENSOR PM PATIENTS: IS A DUAL SENSOR APPROPRIATE? INSIGHTS FROM THE DUSISLOG STUDY: 25.8
- Author
-
Pieragnoli, P., Landolina, M., Moro, E., Orazi, S., Vicentini, A., Maglia, G., Pensabene, O., Gulizia, M., Raciti, G., and Padeletti, L.
- Published
- 2007
4. WHICH PATIENTS EXPERIENCE MARKED PACING THRESHOLD FLUCTUATIONS AFTER PACEMAKER IMPLANT WITH AUTOMATIC CAPTURE? INSIGHTS FROM THE ITACA STUDY: 25.7
- Author
-
Pecora, D., Moranti, F., Liccardo, M., Pepi, P., Orazi, S., Sartori, P., Piraino, L., Caico, S. I., Raciti, G., and Del Giudice, G. B.
- Published
- 2007
5. CARDIAC PACING THERAPY IN PATIENTS WITH BIFASCICULAR BLOCK AND UNEXPLAINED SYNCOPE: A PRESS STUDY: 23.8
- Author
-
Giada, F., Castro, A., Loricchio, M. L., Giaggioli, G., Orazi, S., Viscosi, M., Bartoletti, A., Calò, L., Inama, G., Marras, G., Ricci, R., and Santini, M.
- Published
- 2007
6. GENDER DIFFERENCES AMONG ISCHEMIC PATIENTS IMPLANTED WITH ICD FOR PRIMARY PREVENTION: DATA FROM CAMI GUIDE STUDY: 13.2
- Author
-
Landolina, M., Vicentini, A., Castro, A., Orazi, S., Diotallevi, P., Sassara, M., Padeletti, L., Pozzolini, A., Accardi, F., Raciti, G., Biasucci, L. M., and Bellocci, F.
- Published
- 2007
7. DO PATIENTS IMPLANTED WITH ICD FOR PRIMARY PREVENTION MATCH THE CHARACTERISTICS OF THE POPULATION OF CLINICAL TRIALS? INSIGHTS FROM THE CAMI GUIDE POPULATION STUDY: 13.3
- Author
-
Bellocci, F., Biasucci, L. M., Giubilato, G., Vicentini, A., Castro, A., Orazi, S., Diotallevi, P., Sassara, M., Kheir, A., Zuin, G., Achilli, F., and Raciti, G.
- Published
- 2007
8. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry
- Author
-
Fauchier, L., Greenlaw, N., Ferrari, R., Ford, I., Fox, K. M., Tardif, J. -C., Tendera, M., Steg, P. G., Sokn, F. J., Reid, C., Lang, I., Van den Branden, F., Cesar, L. M., Mattos, M. A., Nazar Luqman, H., Goudev, A., Dorian, P., Hu, D., Widimsky, P., Hassager, C., Danchin, N., Kaab, S., Vardas, P., Sulaiman, K. J., Al Mahmeed, W., Al Suwaidi, J., Al Rashdan, I., Abdulkader, F., Merkely, B., Kaul, U., Daly, K., Tavazzi, L., Jang, Y., Erglis, A., Laucevicius, A., Jamaluddin, A. N., Gamba, M. A., Tulevski, I. I., Stepinska, J., Morais, J., Macarie, C., Oganov, R., Shalnova, S., Al-Zaibag, M., Hou, M. K., Kamensky, G., Fras, Z., Kanic, V., Naidoo, D. P., Zamorano, J. L., Rickli, H., Jaussi, A., Sriratanasathavorn, C., Kalra, P., Lutai, M., Oleksandr, Nguyen, L. V., Henry, R., Ahuad Guerrero, A., Basara, M., Belcastro, F., Bertarini, J. A., Cazenave, C., Dreycopp, H., Egido, J., Estrella, J., Garofalo, D., Giordano, J., Lagioia, H., Lago, N., La Greca, R., Lema, L., Lopez Cabanillas, N., Luquez, H., Miller, C., Prada, E., Rodenas, P., Schena, R. G., Suarez, G., Tomatti, A., Colquhoun, D. M., Conradie, A., Cox, S., Cross, D., Fathi, R., Fitzgerald, B., Hamilton-Craig, I., Holt, G., Jayasinghe, S. R., Mai, N., Moolman, J., Motyer, R. A., Phillips, K., Rafter, A., Rahman, A., Rainbird, A., Scalia, G., Taylor, A., West, P., Alford, K., Amor, R., Astridge, P., Bastian, B., Bates, F., Doohan, M. M., Du Plooy, J., Ford, J. C., Kanagaratnam, L., Khoury, V., Parkin, R., Rogers, J., Sceats, G., Waldman, A., Wang, D., Wright, S., Ardill, J., Aylward, P., Beltrame, J. F., Bradley, J., Heddle, W., Joseph, M., Rajendran, S., Varughese, S., Brice, E., Hockings, B., Janssen, J., Kozlowski, A., O'Shea, J., Playford, D. A., Woollard, K., Ajani, A., Barron, G., Better, N., Chan, B., Chan, R., Cotroneo, J., Counsell, J. T., Eccleston, D. S., Forge, B. H. R., Hamer, A., Horrigan, M., Jelinek, V. M. J., Lew, R., O'Donnell, D., Panetta, F., Sebastian, M., Soward, A., Srivastava, P., Strathmore, N. F., Sylivris, S., Szto, G., Veth, V., Yip, T., Badr-Eslam, R., Kleemann, L., Steurer, G., Morz-Proszowski, B., Auhser, F., Teleky, U., Sepp, G., Beinhauer, A., Kero, D., Lavicka, C., Perger, T., Hadjiivanov, V., Feldner-Busztin, M., Mika, R., Filip, W., Mahr, A., Toplak, J., Millauer, M. G., Haralambus, P., Walcher, K., Karner, K. H., Ziak, E., Painsipp, P., Frank, U., Suntinger, A., Gritsch, W., Bode, G., Herrmann, R., Raffelsberger, R., Topf, H., Moser, E., Fochterle, J., Honsig, T., Mayr, K., Mayr, H., Kaserbacher, R., Dzien, A., Galehr, E., Felbermayer, M., Schwarz, R., Amini, R., Appeltants, H., Ballet, A., Bar, J. -P., Beckers, J., Bergen, J. -M., Berkenboom, G., Bernard, X., Bouvy, T., Briki, R., Claeys, M., Dascotte, Y., Davin, L., De Backer, T., De Keyser, F., De Meester, A., De Ridder, S., Dendale, P., Denef, K., Dhondt, E., Emonts, M., Geraedts, J. T. M., Goethals, M., Gregoire, J. -M., Haine, E., Herbots, T., Hoffer, E., Hutse, W. H. J., Kassab, A., Lafontaine, P., Lancellotti, P., Lefebvre, P., Lesseliers, H., Lozano, A., Maamar, R., Martinez, C., Noel, J. -F., Odent, G., Pasquet, A., Peperstraete, B., Purnode, P., Rogowsky, A., Rosseel, M., Salembier, J. -P., Surmont, P., Thermol, P., Vandeplas, A. M. F., Van de Walle, S., Vandergoten, P., Vanhauwaert, B. G., Vanneste, L., Vercammen, J., Verleyen, D., Vermander, D., Vervoort, G., Weytjens, C., Yanni, N., da Costa Pereira, A., Rocha de Lorenzo, A., Felice Castro Issa, A., Mahler Mioto, B., de Brito Vianna, C., Segre, C. A. W., Grupi, C. J., Okawabata, C., Favarato, D., Giusti Rossi, E., Fernandes, F., Pitella, F., Alvarez Ramires, F. J., Henpin Yue Cesena, F., Monteiro Ferreira, J. F., Junior, J. F., Tonet, L., Nastari, L., Machado Cesar, L., Gowdak, L. H., Matos, M. A., Moretti, M., Morgado, P. C., Vicente Amato, R., Tadeu Munhoz, R., Coimbra, S. R., Luqman, H. N., Yakovova, S., Mantcheva, M., Mincheva, V., Baurenski, L., Karastanev, K., Yordanova, V., Peneva, Y., Bailey, A., Wong, P., Fagan, M., Sabe-Affaki, G., Villasenor, F. M., Belisle, P., Son, W. K., Manyari, D. E., Giacomantonio, N., Lubelsky, B. J., Ezekiel, D., Leong, J. C. S., Grover, A., Vavougios, J., Pesant, Y., Kushner, A. M., Yeung, M. M. M., Vertes, G. E., Nasser-Sharif, F. J., Abdulla, A. H. K., Spensieri, D., Roy, A., Nguyen, T. T., Leclair, M., Morra, P., Everton Biglow, C., Baril, J. F., Lai, K., Wong, D. S., Martinho, V., Antoniadis, G. A., Searles, G. R., Rouse, D., Brisson, G., King Wong, S., Collette, R. S., M. S. C., Ho, Constance, C., Gendreau, R., Kellam, G. W., Cieza Lara, T. A., Boyrazian, H. A., Shamsuzzaman, M., Spink, D. R., Wong, A. P. T., Grewal, R. S., Che, C., Janes, J., Hechtenthal, N., Czarnecka, M., Saulnier, D., Levesque, G., Clavette, P. F., Kennedy, D. R., Kokis, A., Orenstein-Lyall, T. L., Shekhar Pandey, A., Robb, J., Verret, G., Czarnecki, W., Tsui, W. W. H., Perreault, F., Chouinard, G., Lafrance, G., Fullerton, G. M., Lavoie, J. P., Le Bouthillier, P., Tran, Q. H., Rodriguez Marrero, I., Ramadan, F. B., Talbot, P., Fazil, M. A., Cha, J. Y. -M., Garg, S., Chehayeb, R., Roy, B., Chan, Y. K., Harlos, H. E., Matheson, H. B., Patel, R., Vaz, G. F., Bhatt, J. S., Liu, E., Ashton, T. H., Sullivan, H., Quinn, L. P., Yared, K., Gupta, A., Sullivan, B., Campbell, J., Pallie, S., Kim, H., Vizel, S., Savard, D., Cherry, J. M., Gold, J., Chiu, S., Brouillette, G., Singh, R. R., Varma, S., Belanger, A., Myburgh, J. L., Berlingieri, J., Nisker, W., Boutros, G., Bakbak, A. I., Healley, W., Lasalle, L., Liu, F., Tu, C., Lv, S., Liu, X., Gao, H., Li, H., Zhao, H., Cao, L., Zhao, S., Wang, Y., Wu, D., Gu, F., Pan, G., Liu, P., Wang, X., Jiang, H., Li, J., Wang, J., Zhang, L., Ke, Y., Li, D., Chen, G., Xue, H., Jin, Q., Dong, W., Chen, Y., Fu, Z., Hu, H., Liang, Q., Yang, X., Zhou, Z., Xu, Z., Shao, C., Zhang, H., Pei, H., Song, L., Yu, M., Guan, T., Tang, Y., Wu, Y., Yang, M., Ceng, Q., Chen, X., Lin, L., Peng, Y., Yan, X., Yao, E., Zheng, X., Chen, B., Chen, H., Chen, W., Wang, R., Zheng, Y., Tan, H., Zhou, S., Zhou, Y., Liu, Z., Lu, Q., Lai, L., Pan, J., Wang, L., Fu, Q., Peng, J., Du, N., Lv, Y., Miao, W., Wang, H., Pu, Y., Wang, T., Dong, M., Gong, L., Zhang, J., Chen, Z., Jiang, Q., Ma, F., Xu, W., Dai, M., Wu, J., Yu, X., Chen, C., Huo, Y., Sun, L., Gao, W., Li, Z., Hu, Y., Chen, M., Li, G., Xue, M., Yao, Y., Pan, X., Sang, Z., Zhao, G., Hang, J., Ma, S., Zhang, G., Zhou, G., Li, W., Zhu, B., Yu, B., Zhu, S., Mao, J., Xu, M., Liu, Q., Huang, Q., Xie, Y., Feng, L., Chen, F., Chen, L., Liu, Y., Pei, X., Sun, A., Tian, Z., Wang, W., Yang, H., Yu, A., Zhang, M., Zhang, C., Guan, X., Zhou, X., Li, Y., Xing, Y., Chen, K., Luo, L., Dong, S., Zhang, Y., Ai, F., Xiong, C., Yang, F., Yang, K., Yan, J., Zhu, M., Zhang, A., Shan, G., Chen, J., Guo, J., Wu, S., Li, L., Liu, R., Yang, Y., Gao, X., Du, Z., Liang, L., Zhao, Y., Qian, J., He, L., Xiong, L., Chen, P., Peng, C., Zhu, J., Liu, J., Xie, X., Jiang, F., Li, A., Yang, Q., Cong, H., Guo, Y., Ren, N., Xiao, J., Zhao, R., Jiang, J., Deng, X., Wang, S., Wu, K., Zhang, X., Du, W., Shuang, D., Wei, J., Yuan, C., Li, F., Ou, X., Ou, Y., Yu, G., Zhang, S., Gao, J., Qian, Z., Wu, G., Zheng, S., Xu, D., Xie, J., Ren, W., Yao, X., Cai, B., Lv, J., Dong, J., Deng, Z., Bozkova, J., Carda, J., Dedkova, S., Dufka, A., Fridrich, J., Hodac, T., Jirmar, R., Kadleckova, A., Karlicek, M., Krupicka, J., Kuchar, J., Lavicka, V., Leso, J., Lorenc, Z., Micko, M., Navratil, P., Petrova, I., Povolna, P., Raisova, L., Raska, P., Ravlyk, V., Schlesingerova, S., Smrckova, E., Sternthal, P., Stursova, H., Vymetal, P., Zaoral, L., Wiggers, P., Markenvard, J., Andersen, L. K., Frost, L., Refsgaard, J., Strange, S., Egstrup, K., Sykulski, R., Hildebrant, P., Haghfelt, T., Ege, M., Cattan, S., Adam-Blanpain, M., Adda, M., Aimouch, N., Ardouin, L., Assouline, S., Aumjaud, A., Barjhoux, C., Baroudi, R., Beaurain, C., Bennouna, M. A., Bernard, A., Bernardeau, C., Blanc, E., Blum-Decary, I., Bodur, G., Boesch, C., Bonal, J., Bonhomme, R., Bonnet, J. L., Bories, J., Bourachot, M. L., Brumelot, F., Brunehaut Petaut, M., Brunschwig, C., Buffet, P., Calmettes, P., Centa, I., Chartier, B., Chemin, P., Chometon, F., Cohen, J., Colin, R., Cottin, Y., Crespo, F., Dabboura, A., David, F., Dehayes, P., Dematteo, P., Dibon, O., Dodemant, P., Dormagen, V., Dreyfus, X., Dubois, J. M., Duclos, F., Ducoudre, M., Duprez, O., Durand, P., Durand, E., Egloff, P., Escande, M., Escourrou Berdou, M. C., Esna Ashari, G., Feldmann, I., Ferrieres, J., Foltzer, E., Fontanet, B., Garandeau, M., Garban, T., Geffroy, S., Gillet, T., Godart, S., Gosse, P., Gratia, P., Greiner, O., Gueusquin, A., Guiu, E., Guy, J. M., Haddad, S., Hennebelle, V., Honorat, S., Hourany, A., Hua, G., Jacquier, P., Jean, S., Jeremiasz, R., Kohler, P., Lacroix, A., Leandri, M., Lemiere, Y., Liautard, M., Loheac, P., Louchart, J. C., Magnus, P., Maheu, B., Malaterre, H. R., Manchet, G., Mantoux, J., Manzi, D., Marachli, M., Maroun, M., Meneveau, N., Messas, E., Mougeolle, J. L., Mouhat, T., Muller, J. J., Naisseh, M., Nocon, P., Onger, D., Ouguoujil, A., Ovize, M., Page, E., Pareathumby, K., Pleskof, A., Poinson, P., Pons, G., Pouderou, P., Poujois, J. N., Probst, V., Prunier, F., Prunier, L., Puel, V., Rechtman, D., Rennert, R., Rijavec, B., Riou, Y., Robert, J., Roche, C., Roul, G., Salaun, B., Saleh, B., Sandalian, A., Sander, M., Schenowitz, A., Silvestre, A., Soleille, H., Tabet, S., Tardy, M., Thomas-Richard, F., Truong, B., Varaldi, J., Vial, H., Walch, J. M., Wazana, M., Zeitouni, R., Audibert, H., Alizon, F., Amlaiky, A., Asplanato, M., Baranes, C., Bariaud, M., Bernasconi, F., Bousquet, P., Ceraulo, C., De Geeter, G., Donetti, J., Doucet, B., Doucet, J., Dutoya, T., Ennouchi, D., Fallacher, M. H., Fouquet, G., Fourchard, V., Gdalia, J., Grollier, G., Guerard, S., Jeannerat, P. A., Jobic, Y., Joulie, V., Jourdain, P., Jouve, V., Ketelers, R., Khaznadar, G., Kohan, P., Koujan, B., Lammens, B., Landragin, I., Le Moal, E., M'Bey, D., Maes, F., Maheas Morlet, S., Massabie, R., Meddah, D., Meriaux, F. X., Mestre-Fernandes, C., Meyssonnier, P., Migliore, M., Milewski, J., Millet, J. F., Mingam, S., Nazeyrollas, P., Paganelli, F., Pellerin, F., Petitjean, F., Pinzani, A., Pladys, A., Primot, P., Pucheu, A., Rahali, A., Ravoala, P., Rousson, D., Samama, P., Sardon, M., Silvestri, R., Soskin, P., Tabone, X., Tricot, C., Vaquette, B., Vogel, M., Weingrod, M., Aboyans, V., Amoretti, R., Aubry, J., Berthezene, P., Binet, D., Bonnaud, X., Bonnet, P., Bonny, A., Bouchaya, T., Boureux, C., Bourgeois, J. M., Brottier, L., Cavert, B., Cleron, S., Dechoux, E., Delhomme, C., Detienne, J. P., Dubs, J. P., Faudon, B., Fellous, F., Fressonnet, R., Garaud, Y., Garcia, D., Geneves, M., Gleizes, J. L., Guyetand, C., Hermellin, B., Iovescu, D., Kanner, J. P., Khanoyan, P., Leherissier, A., Maximovitch, A., Merian, B., Messali, P., Moreau, Y., Moyal, J., Payot, L., Petoin Peuch, L., Prevot, J. L., Raymond, P., Relange, D., Reymond, S., Robert, J. F., Rosenstein, H., Schneider, J., Schultz, R., Tanielian, P., Thoin, F., Thomas, L., Touzet, P., Steg, G., Amiel Oster Sauvinet, G., Baylac Domengetroy, F., Chamou, K., Etcheverry, B., Farges, J. L., Fraboulet, J. Y., Goralski, M., Janody, D., Mamez, B., Manlay, W., Paillard, F., Pelier, F., Petit, A., Skonieczny, M., Augarde, R., Fournier, J. B., Liandrat, S., Lim, P., Noury, A. I., Paris, D., Saade, M., Stordeur, J. M., Pornin, M., Galinier, M., Balice-Pasquinelli, M. A., Sosner, P., Yvorra, S., Delcoulx, E., Mouquet, F., Poulard, J. E., Sudre, A., Heno, P., Biausque, F., Guenoun, M., Attia, G., Pouwels, S., Carpentier, L., Verbrugge, E., Ziccarelli, C., Elkohen, M., Tricoire, J., Lang, P., Huttin, O., Altevogt, B. -M., Altmann, U., Baar, M., Berrisch-Rahmel, S., Birkenhagen, A., Blase, I., Blindt, R., Bosch, R., Brattstrom, A., Breuer, H. -H., Castrucci, M., Cicek-Hartvig, S., Cierpka, R., Claus, M., Deissner, M., Drexler, M., Eggeling, T., Eisele, G., Enayat, D., Frickel, S., Gessner, S., Giokoglu, K., Gmehling, J., Goss, F., Grooterhorst, P., Gysan, D. B., Haberl, R., Haerer, W., Hassler jun, N., Heinemann, S., Henschel, F., Hinrichsen, M., Hofer, W., Hofmeister, A., Hoh, G., Horstkotte, E., Jager, F., Jeserich, M., Keil, U., Killat, H., Kimmel, S., Kindel, M., Kindler, P., Kleta, S., Konemann, J., Konig, K., Krause-Allmendinger, H., Kronberg, K., Kruck, I., Mannl, V., Meinel, A., Mentz, G., Meyer-Michael, E., Mibach, F., Moller, S., Muth, S., Nelbock-Huber, E., Ohlmeyer, D., Ozkan-Rashed, Z., Paulus, C. -P., Perings, S., Placke, J., Raters, C., Reifart, N., Rink, A., Rybak, K., Salecker, I., Schermaul, K. -H., Schmidt, E., Schmitz, K. -H., Schon, N., Schroder, T., Sievers, B., Simon, M., Spengler, U., Speth-Nitschke, M., Stumpp, A., Szabo, S., Taggeselle, J., Tamm, A., Thelemann, A., Thelemann, C., Thummel, H., Unger, G., Utech, A., Volmar, J., Wauer, B., Wehr, G., Weinrich, L., Weinrich, R., Windstetter, U., Wirtz, J. H., Wittlich, N., Ziehn, P., Zundorf, P., Al Wahshi, Y., Singh, P. P., Narayan, A., Al Tamimi, F., Al Yazeedi, J., Ayche, M., Al Lawati, A., Al Dhanki, M., Salustri, A., Al Sousi, A., Salah, T., Tamimi, M. Y., Agrawal, A., Wassef, A., Baslaib, F., Al Radaideh, G., Yusufali, A., Bazargani, N., Akbar, M., Abdel Wahab, H., Abdel Malak, S., Ghaly, I., Al Ghool, S., Al Kandari, F., Haiba, M., Alanbaei, M., El Menyar, A., Gomaa, M. M., Khalifa, A., Garadah, T., Avgerinos, C., Gouli, O., Stergiou, D., Alexopoulos, I., Pappas, C., Petropoulos, I., Chatzioakim, G., Pontikakis, N., Priftis, C., Mpompoth, P., Bourazanis, I., Papathanasioy, A., Avlonitis, S., Zakopoulos, C., Koutsimpanis, G., Tsamopoulos, I., Christoforidis, C., Zachos, V., Kalaras, P., Karachaliou, M., Liatas, C., Pournaras, G., Theodorakis, G., Orestis, I., Panisois, K., Chalkiadakis, E., Arfaras, V., Melainis, Kolios, G., Boutsikos, P., Kotsalos, A., Mitropoulos, D., Samothrakitis, A., Svolis, K., Anastasiou, E., Gkinis, T., Dalampyras, P., Kalampalikis, A., Leontaridis, I., Gabriilidis, S., Konstantinidis, I., Plastiras, V., Tarenidis, P., Marozsan, I., Edes, I., Czuriga, I., Cziraki, A., Toth, K., Dongo, A., Turi, P., Forster, T., Borbola, J., Bachmann, B., Masszi, G., Orban, M., Gerges, G., Balogh, G., Bajcsi, E., Sereg, M., Dezsi, C. A., Takacs, I., Nagy, L., Kisjos, B., Janosi, A., Nagy, A., Nagy, K., Buttl, A., Lippai, J., Sziegl, Z., Malkocs, Z., Foldi, A., Fikker, K., Szabo, E., Gupta, R., Natarajan, S., Dalal, J., Saran, R. K., Mehta, A., Samal, M. P., Khan, I. A., Ghose, T., Sawhney, J. P. S., Roy, T., Chandra, S., Modi, S., Singh, M. M., Vijayaraghavan, G., Sreenivasa Murthy, L., Ramesh, S. S., Dayasagar Rao, V., Chenniappan, M. S., Vadavi, A., Kunhali, K., Srinivasa Reddy, K., Thillai Vallal, S., Khera, P., Dasbiswas, A., Ganguly, K., Chatterjee, S. S., Prasad, B., Shukla, D., Trivedi, A. K., Ahuja, R., Deb, J., Rawal, J., Karnik, R., Hiremath, M. S., Kumbla, D. K., Shetty, S. R., Chonkar, N. S., Juneja, L. M., Goyal, B. K., Sheahan, R., Mulvihill, N., Vaughan, C., Fleming, S., Shiels, P., Keelan, P., Kiernan, T., Cosgrave, J., Day, B., Kelly, K., MacNamara, F., Maguire, B., Clifford, A., O'Gara, A., Guardigli, G., Riccioni, G., Pedretti, R., Felis, S., Pernice, V., Lillo, A., Gori, P., Zaca, F., Giacomazzi, F., Terrosu, P., Cernetti, C., Antonicelli, R., Ansalone, G., Balbi, M., Tamburino, C., Tantillo, S., Proietti, F., Mallamaci, V., d'Este, D., Silvestri, F., Magliari, F., Capuano, N., Marchionni, N., Turiel, M., Maxia, P., Marullo, L., Vicentini, A., Pes, G., Caridi, G., Grieco, A., Doronzo, B., Lacche, A., Massari, F., Orazi, S., Antonelli, G., Provvidenza, M., Nicolino, A., Servi, S. D., Sinicropi, G., Maragoni, G., Azzolini, P., Brscic, E., Bongo, A. S., Perna, G., Perna, B., La Rosa, C., Mossuti, E., Ferrante, R., Petrillo, M. E., Castellari, M., Di Pasquale, P., Saporito, F., Alitto, F., Testa, R., Kang, S. M., Koo, B. K., Hong, S. K., Kim, W., Lee, S. H., Seo, H. S., Gwon, H. C., Kang, D. H., Kwon, H. M., Chae, I. H., S. J., Oh, Shin, J. H., Goh, C. W., J. H., Zo, Hong, T. J., Kim, D. S., Cha, T. J., Ryu, J. K., Kim, Y. J., Hwang, J. Y., Hur, S. H., Jeong, M. H., S. K., Oh, Jin, D. K., Jung, K. T., Rhew, J. Y., Lee, S., Jeon, D. W., Kim, S. H., Mintale, I., Latkovskis, G., Hansone, S., Rozkova, N., Baika, A., Jasinkevica, I., Abele, S., Laizane, I., Pontaga, N., Ecina, V., Mihailova, I., Kondratovica, A., Jurgaitiene, R., Slapikas, R., Barauskiene, G., Jankauskiene, E., Reviene, S., Vaisvila, T., Zaronskiene, D., Slapikiene, O. B., Kupstyte, N., Rinkuniene, E., Steponeniene, R., Kojeliene, J., Badariene, J., Dzenkeviciute, V., Sadauskiene, E., Butkuviene, I., Stankevicius, R., Paliulioniene, R., Snikyte, R., Mazutavicius, R., Abdul Rahim, A. A., Mohamed Yusof, A. K., Chee, K. H., Sadiq, A., Ramanaidu, S., Sim, K. H., Ong, T. K., Fong, A. Y. Y., Chang, B. C., Chua, S. K., Cham, Y. L., Moh, d. Amin N. A., Tan, S. K., Chandran, K., Cheah, Y. W., Sinnadurai, J., Choor, C. K., Sia, K. K., Ang, C. C., Singh, J., AbdulWahab, M. Z., Ghapar, A. K., Muthu, A., Kauthaman, M., Jaafar, A. H., K. H., Ng, Tahir, A. R., Abdul Manap, H., Ch'ng, B. S. K., Ch'ng, E. T., Ismail, O., Sahar, A. S., Abdul Kareem, B. B., S. K., Ma, Liew, H. B., Bhaskaran, R. K. M., Shah, R. P., Joseph, K. L., Noor Hasni, H., W. K., Ng, Choo, G. H., Yeo, C. K., Lai, V. M., Lai, Y. C., Tay, M. H., Lim, B. A., Esperon, G. L., de Jeus Zuniga Sedano y America Alvarez, J., Azar Manzur, F., Jerjes Sanchez, C., Cerda Rojas, J., Carrillo Calvillo, J., Petersen Aranguren, F., Martinez Sanchez, C., Vieyra, G., Gonzalez Romero, S., Puente Barragan, A., Redding Escalante, F., Chavez Paez, J., Fernandez Valadez, E., Gaxiola, E., Manautou, L. E., Henne Otero, O., Barrera Bustillos, M., Leyva Pons, J. L., Gomez Alvarez, E., Romo Santana, J. R., Martinez Redding, J., Arias Mendoza, A., Rodriguez Briones, I., de Jeus Rivera Arellano, J., Arenas Leon, J. L., Alcocer Gamba, M., Alexanderson, E., Ruiz Esparza, M. E., Elizondo Sifuentes, L. A., Briseno, J. L., Sandoval, S., Castro, A., Cue Carpio, R., Rodriguez, E., Rojas, G., Solache, G., Diaz, R., Baleon, R., Ferreyra Solorio, C., Alberto Ramirez Reyes, H., Lopez Martinez, M., Romero Maldonado, M. A., Escobedo de la Pena, J., Hilario Jimenez Orozco, J., Reyes Cisneros, F. A., Alvarez Gil, J., Bautista, G., Lopez, Odin de los Rios Ibarra, M., Somsen, G. A., Wittekoek, J. E., Miedema, K., de Sauvage Nolting, P. R. W., Chlewicka, I., Brodzicki, P., Stasiuk, T., Szalkowski, P., Kulig, W., Maliszewski, M., Krolicka, K., Zdrojewska, J., Nikodemska, I., Szpak, A., Wrebiak-Trznadel, M., Prokop, A., Szulc, M., Olszewski, A., Kepa, W., Banach, J., Weglarz, M., Galuszka-Bilinska, A., Krolak, A., Cisowska-Drozd, E., Orzechowski, K., Jezewska, M., Adamaszek, K., Glanowska, G., Pitsch, T., Matuszewska, G., Nowowiejska-Wiewiora, A., Deren, M., Walawski, G., Soltysiak, M., Wysocki, R., Jarosinski, G., Drzewiecka, A., Lugowski, T., Jankowska, A., Blaszczak, P., Drozd, J., Lotocka, E., Duchowska, R., Sobczyk, D., Jarmuzek, P., Sidor, M., Adamczyk-Kot, D., Sudnik, J., Cygler, J., Skoczylas, I., Poprawa, B., Kisiel, L., Kossowska, U., Sikorska-Buczkowska, B., Modzelewska, K., Demianiuk, B., Streb, W., Mularek-Kubzdela, T., Bogdanski, P., Kazmierczak, E., Zimolag, R., Lorenc, J., Furtak, R., Regulska, A., Winter, M., Fic, M., Turek, P., Nowicka, E., Bryl, W., Lenartowska, L., Jerzykowska, O., Mackow, M., Gadzinski, W., Kacorzyk, R., Zalewska, D., Sadlowski, R., Slaboszewska, J., Gruchala, M., Frankiewicz, A., Walczewska, J., Adamkiewicz-Piejko, A., Chyrek, R., Jankowska, L., Correia, A., Girao, A., Herdade, A., Sequeira, A., Tavares E Taveira, A., Gonzaga, A., Ribeiro, A., Albuquerque, A., Fernandes, A., Estriga, A., Rocha De Almeida, A., Lourenco, A., Pereira, A., Faria, A., Carvalho De Moura, B., Camossa, C., Alves, C., Aguiar, C., Rodrigues, C., Wellenkamp, E., Lins, E., Fernandes De Sousa, F., Moreira Pinto, F., Matias, F., Silva Alves, G., Braganca, G., Proenca, G., Pego, G., Vinhas, H., Arroja, I., Rosa Pais, J., Silva E Sa, J., Vasconcelos, J., Matos, J., Freitas, J., Ferreira, J., Costa, J., Alcaravela, J., Mimoso, J., Antunes, J., Ferreira Dos Santos, J., Nobre Dos santos, J., Tito Martins, J., Fernandes, J., Chambel De Aguiar, J., Moreira, J., Carvalho, J., Forte De Carvalho, J., Calaca, J., Simoes, L., Lopes Antunes, L., Soares, L., Semedo, L., Macedo, L., Sargento, L., Basto, L., Carpinteiro, L., Rebelo, L., Oliveira, L., Catarino Carvalho, M., Alves Costa, M., Gamboa, M. C., Ferrao E Vasconcelos, M. F., Custodio, M. H., Mendonca, M. I., Pinto Vaz, M. J., Espiga De Macedo, M., Lazaro, M., Martins Oliveira, M., Pelicano, N., Lousada, N., Rodrigues, O., Matos Dias, P., Fonseca, P. F., Ferreira, P., Abreu, P. E., Monteiro, P., Seabra Gomes, R., Carvalho, R., Santos, R., Pires Pereira, R., Rosado Soares, R., Baptista, S., Reis Monteiro, S., Gil, V., Sanfins, V., Martins, V., Anghel, M., Arsenescu Georgescu, C., Babes, K., Banu, M., Beyer, R., Bratu, I., Bumbu, A., Capalneanu, R., Chioncel, O. D., Chiscaneanu, T., Christodorescu, R., Cindea Nica, N., Cinteza, M., Coman, S., Constantinescu, M., Craiu, E., Dan, G. A., Dan, D. C., Dan, A., David, C. M., Dorobantu, M., Farcas, D., Firastrau, V., Florescu, C., Ghicu, A., Giuca, A., Grigoriu, R., Ionescu, D. A., Ionescu, D. D., Iosipescu, L. C., Ivan, M. V., Lighezan, D., Magheru, S., Magherusan, M., Marinescu, S. M., Motoc, A. C., Musetescu, R., Rau, M., Rotaru, L., Rus, H., Sirbu, O., Sorodoc, L., Spinu, C. M., Stanciulescu, G., Statescu, C., Toringhibel, M., Trambitas, R., Trocan, N., Tudose, A., Vinereanu, D., Zagreanu, M., Dymova, D., Semenova, N., Zherebtsova, A., Fedoskin, V., Gurianova, N., Bolotova, N., Knyazeva, V., Spitsina, T., Sytilina, N., Atamanchuk, N., Giorgadze, M., Zarechnova, S., Kutuzova, S., Sharapova, Y., Stelmakh, I., Sinyukova, O., Rostik, S., Evtukhova, L., Sukhanova, L., Makhieva, T., Tereshko, S., Kolesnikov, V., Kochurov, E., Marchenko, B., Nurgalieva, S., Galeeva, Z., Andreicheva, E., Zakirova, V., Baleeva, L., Minsafina, A., Borodina, N., Arkhipova, Y., Krechunova, T., Scherbak, M., Merkhi, A., Aksyutina, N., Ratovskaya, O., Suglobova, E., Kozhelenko, Y., Potapova, E., Poluyanova, G., Naberezhnova, N., Daniels, E., Atueva, K., Tsaryabina, L., Kurekhyan, A., Khishova, N., Dubinina, E., Demina, O., Mochkina, P., Bukanina, E., Tolpygina, S., Polyanskaya, Y., Malysheva, A., Kheliya, T., Serazhim, A., Voronina, V., Lukina, Y., Dubinskaya, R., Dmitrieva, N., Kuzyakina, M., Khartova, N., Bokuchava, N., Smirnova, E., Esenokova, A., Pavlova, Y., Smirnova, O., Astrakhantseva, P., Bykovskaya, S., Charikova, O., Berdnik, K., Karaseva, T., Zhabina, L., Oleinikova, N., Dzhkha, O., Grigoryan, S., Yakovenko, E., Ivaschenko, T., Kiseleva, I., Shokina, T., Novikova, M., Khodanov, A., Popova, L., Latyntseva, L., Kilaberiya, O., Makarenkova, K., Nosova, N., Gerasimova, T., Boikova, L., Sharapova, N., Kulikova, Y., Pasechnaya, N., Bulakhova, E., Kurochkina, S., Bratishko, I., Likhobabina, O., Panova, E., Voronina, N., Bizyaeva, N., Gusev, O., Nevolina, N., Arsentieva, T., Budanova, I., London, E., Melnikova, Khripun, A., Polyaeva, L., Osadchuk, E., Krasnoslobodskaya, O., Yakimova, N., Lugin, A., Sosnova, Y., Il'ina, E., Kositsina, G., Shanina, I., Kostomarova, S., Malgina, M., Omelchenko, M., Gorlova, I., Eidelman, S., Salakhova, A., Bondarenko, B., Sopia, R., Baboshina, N., Eliseeva, N., Tumarov, F., Petrochenko, N., Khudina, I., Arabadzhi, N., Samakhovets, V., Tkhorzhevskaya, L., Sinotova, T., Zherlitsyna, E., Minkin, S., Petrova, N., Tikhonov, Y., Shmakova, N., Abduvalieva, V., Kuzmicheva, M., Nikolaeva, L., Varezhnikova, O., Dmitrieva, T., Mikhailova, E., Yanina, Y., Kapustina, L., Vazhdaeva, Z., Golovina, G., Fedorova, N., Nikolaeva, I., Fillipova, O., Gareeva, L., Tuktarova, F., Khmelevskikh, N., Karnot, V., Golub, M., Surovtseva, I., Kulygina, V., Shelomova, N., Kruglova, I., Pokrovskaya, I., Rodina, O., Polkina, L., Biryukova, N., Filippova, E., Kotova, E., Ignatieva, T., Alekseeva, T., Gruznykh, L., Mozerova, E., Moksyuta, E., Kosachek, E., Srtumilenko, N., Baranova, O., Voronova, T., Bayakhchan, L., Grudtsina, I., Gorshkova, L., Shamsutdinova, O., Getman, M., Gorodilova, I., Karnaukhova, N., Rotenberger, V., Isaeva, L., Lebischak, G., Ryzhkova, V., Usoltseva, E., Mescharekova, D., Tavlueva, E., Mineeva, E., Stikhurova, M., Kosareva, L., Grechishkina, O., Nikishina, S., Ilyukhina, A., Gureeva, O., Soin, I., Erofeev, S., Lebedev, S., Kudryavtsev, L., Gamzatov, E., Maximchuk, N., Grekhova, L., Kolevatova, L., Kazakovtseva, M., Kolesova, O., Zharikova, L., Kukaleva, V., Starostina, N., Grushetskaya, I., Kazachkova, V., Pashentseva, I., Shimonenko, S., Sirazov, I., Chernozemova, A., Golubeva, O., Mingalaeva, S., Zatsarina, E., Kozlov, D., Davydova, N., Larina, O., Fayez Al-Habib, K., Al-Hersi, A., Al-Baker, H., Al-Faleh, H., Moberik, A., Radwan Arafah, M., Al-Shamiri, M., El-Shaer, F., Al Zaibag, M., Bdeir, M., Suliman, I., Mukhtar, A., Omar, H., Jamiel, A., Elkrail, A., Alanazy, M., Habab, M., Ashmak, K., Nourallah, R., Mak, K. H., Singh, B., Baldev, S., Chee, T. S., Koo, C. C., Low, L. P., Nair, V. P., K. S., Ng, Quek, S. S. S., Tan, E. H. M., A. L. R., Ng, Chuang, H. H., Kaliska, G., Murin, J., Hatalova, K., Gaspar, L., Simkova, I., Dubrava, J., Pjontek, J., Pella, D., Banikova, A., Szentivanyi, M., Kovar, F., Benacka, J., Gonos, I., Fazekas, F., Kycina, P., Poles, J., Pernat, A., Veternik, A., Cernic-Suligoj, N., Kerbev, M., Krajnc, I., Zagozen, P., Alam, A., Brown, B., Luke, B., Variava, E., Nethononda, R., Joubert, S., Matthews, P., Nkombua, L., Antia, V., Bhayat, J., George, S. K., Ranjith, N., Vawda, G. H. M., Govender, S., Soosiwala, I., Shein, K., Panajatovic, M., Flores, J., Khan, M. S. H., Blignaut, S., Coetzee, K., Burgess, L., Freeman, V., Theron, H. D., Arnau Vives, M. A., Abardia Oliva, F. J., Albero Martinez, V., Alegret Colomer, J. M., Alegria Ezquerra, E., Almeida Fernandez, C. A., Alvarenga Recalde, N., Alvarez Aunon, A., Alvarez Garcia, P., Amo Fernandez, C., Amoros Galito, C., Ancin Viguiristi, R., Antona Makoshi, J., Aparici Feal, M., Ardiaca Capell, A., Arnedillo Pardo, J., Arquero Garcia, G., Arrarte Esteban, V., Baquero Alonso, M., Barahona Perez, P., Bardaji Mayor, J. L., Barriales Alvarez, V., Batalla Celorio, A., Bierge Valero, D., Blanco Castineiras, J., Bosa Ojeda, F., Botana Penas, C., Brufau Redondo, H., Bruguera Cortada, J., Cabau Rubies, J., Cabrera Sole, R., Calvo Iglesias, F., Cantabrana Miguel, S., Carrillo Cardoso, R., Casanovas Pie, M., Casas Gimenez, P., Castillo Luena, E., Castillo Moreno, J. A., Castillo Orive, M., Chirivella Gonzalez, A., Chopo Alcubilla, J. M., Climent Paya, V., Cobos Gil, M. A., Colomer Martin, J. L., Concepcion Clemente, A., Cortes Sanchez, R., Cremer Luengo, D., Darnes Soler, S., de Andres Novales, J., De Castro Aritmendiz, R., Delgado Prieto, J. L., Diaz Diaz, J. L., Escobar Cervantes, C., Ezcurdia Sasieta, J., Facila Rubio, L., Falces Salvador, C., Federico Zaragoza, P., Fernandez Alvarez, R., Fernandez de la Cigona, F., Fernandez Lazaro, L. A., Fernandez Leoz, L. C., Fernandez Mouzo, R., Fernandez-Valls Gomez, M., Ferreiro Rodriguez, B., Franco Aranda, C., Freire Corzo, J., Fuertes Alonso, J., Fuertes Beneitez, J., Galve Basilio, E., Garcia Garcia, C., Garcia Gonzalez, M. J., Garcia Ortego, S., Garcia Saavedra, V., Garcia-Moll Marimon, J., Gascuena Rubia, R., Gentille Lorente, D., Gervas Pavon, H., Gilabert Gomez, R., Gomez Barrado, J. J., Gomez Doblas, J. J., Gomez Martinez, M. J., Gonzalez Juanatey, C., Gonzalez Toda, V., Gonzalvez Ortega, M., Gordillo Higuero, E., Hernandez Afonso, J., Herrera Fernandez, D., Homs Espinach, E., Idoate Gastearena, A., Irurita Latasa, M., Izquierdo Gonzalez, R., Jaquet Herter, M., Lagares Carballo, M., Lastra Galan, J. A., Limeres Gonzalez, B., Lopez Aranda, M. A., Lopez Barreiro, L., Lopez Gomez, D., Lopez Granados, A., Lopez Mourino, V., Lopez-Sendon, J. L., Mainar Latorre, L., Marin Araez, E., Marin Ortuno, F., Martin Santana, A., Martinez Florez, J., Martinez Gonzalez, J., Martinez Rivero, J. F., Marzal Martin, D., Mazzanti Mignaqui, G. F., Melero Pita, A., Molina Laborda, E., Montero Gaspar, M. A., Mora Robles, J., Morales Gonzalez, J., Moreno Arribas, J., Moreno Casquete, M. T., Moro Lopez, J. A., Moya Lopez, C., Murga Eizagaechevarria, N., Narro Garcia, F., Navarro Manchon, J., Navas Navas, C., Novo Garcia, E., Nunez Gamero, J. A., Ordonez Espana, A., Ortiz de Murua Lopez, J. A., Orts Soler, E., Otero Chulian, E., Pastor Torres, L., Paule Sanchez, A. J., Paz Bermejo, M. A., Pena Perez, G., Perea Egido, J. A., Perez de Isla, L., Perez Ibiricu, S., Perez Martinez, M. A., Perez Paredes, M., Peris Domingo, E., Pinar Sopena, J., Pindado Rodriguez, C., Pinilla Lozano, M. J., Pinero Ramirez, C., Porras Ramos, Y., Ramos Ariznabarreta, F., Rayo Gutierrez, M., Roca Catalan, J. M., Rodriguez Almodovar, A., Rodriguez Collado, J., Rodriguez Fernandez, A., Rodriguez Fernandez, J. A., Rodriguez Hernandez, J. A., Rodriguez Tejero, I., Romeo Castillejo, I., Romero Alvira, D., Romero Hinojosa, J. A., Romero Menor, C., Rossi Sevillano, P., Rueda Calle, E. C., Rueda Soriano, J., Ruiz Perez, P., Sagastagoitia Gorostiza, T., Sainz Hidalgo, I., Sandin Rollan, M., Santaolalla Rodriguez, S., Santas Olmeda, E., Santos Iglesias, J. L., Sanz Rodriguez, M. L., Segura Laborda, I., Serrano Garcia, S., Sevilla Toral, B., Silva Melchor, L., Simarro Martin-Ambrioso, E., Sola Casado, R., Soriano Navarro, C., Soto Ruiz, M. I., Talavera Calle, P., Torres Diaz, P. L., Troncoso Gil, A., Trujillo Berraquero, F., Ulecia Martinez, M. A., Umaran Sanchez, J., Vaticon Herreros, C., Vazquez Garcia, A., Vega Barbado, J. L., Velasco Espejo-Saavedra, E., Vicente Vera, T., Vida Gutierrez, M., Villar Mariscal, C., Vives Bonato, G., Wu Amen, L., Yanes Bowden, G., Yanez Wonenburger, J. C., Zamorano Gomez, J. L., Zarauza Navarro, J., Monnier, P., Forclaz, A., Grobety, M., Schlueter, L., Vuille, C., Nacht, C. A., Evequoz, D., Ciaroni, S., Domine, F., Berube, J., Hellermann, J., Koller, R., Bourgeois, G., Engel, R., Niederberger, C., Stadler, P., Gnadinger, M., Schmied, C., Wettstein, T., Badorff, C., Hilti, P., Chetelat, C. A., Sepulcri, F., Brunner, H., Schindler, J., Kraus, M., Gmur, W., Bouranasompop, C., Jiraroj-ungkun, W., Lapanun, W., Vivekaphirat, V., Panpunnung, S., Dutsadeevettakul, S., Tasneeyapant, S., Ngamjanyaporn, P., Apitamsuntorn, S., Tantisiriwat, W., Suithichaiyakul, T., Kuanprasert, S., Wongcharoen, W., Phrommintikul, A., Musigchai, C., Chantrarat, T., Uerojanaungkul, P., Apinyasawat, S., Tangcharoen, T., Lertnantakul, M., Wasuwat, A., Harinasuta, J., See, O., Chaithiraphan, V., Boonyasirinant, T., Boonyapisit, W., Kittipovanonth, M., Buakhamsri, A., Piyayotai, D., Hutayanon, P., Junejo, S., Aiyegbayo, O., Ancliff, H., Bradshaw, C., Cervenak, R., Choi, H., George, E., Gilmour, I., Gough, D., Idrissi-Sbai, A., Ingham, J., Al-Khalidi, B., Liston, A., Mackrell, J., Pattison, I., Ramachandran, R., Ray, N., Reddy, G., Sen, I., Shetty, K., Singh, L., Stanley, M., Wallace, A., Weatherhead, M., Gilbert, T., McCansh, G., Higgins, S., Killeen, C., Cromarty, I., Franklin, P., Pinch, E., Dhesi, A., Dernedde, C., Lawrence, M., Simper, H., Noble, M., Dalton, G., Stevens, L., Berry, P., Hand, C., Oliver, R., Jones, H., Sampson, P., Taylor, N., Grogono, R., Dalrymple, J., Martin, A., Thurston, S., Elsby, K., Vallis, M., Morrison, G., Lang, C., Watson, A., Thomson, A., Dougall, H., La Hay, B., Compson, L., McCracken, A., Calder, J., Weber, F., Richmond, D., Brownlie, R., Brown, G., MacCowan, H., Heap, A., Perry, M., Holden, L. A., Scott, G., Haldane, N., Hood, S., Cullen, I., Bell, J., McNaught, P., Sharif, M., Dunn, J., Hay, D., Ross, S., Shaw, R., Hay, L., Langridge, S., Burns, R., Crawford, L., Kennedy, A., Logan, D., McAlavey, P., Brown, M., Costello, P., McLaren, G., Potter, A., McPherson, J., Drijfhout, M., Finlayson, J., Troup, D., Woodall, A., Pearce, J., Williams, S., Parkar, W., Yusuf, A., Benett, I., Bishop, P., Thomas, H., Caldwell, I., Ormiston, P., Kwok, S., Kanumilli, N., Saul, P., Milligan, H., Wilkinson, I., Vance, A., Paul, N., Paul, C., Shaikh, I., Ellis, R., Vites, N., Steeds, R., Goodwin, D., Aftab, A., Banham, S., Chauhan, N., Grocutt, M. S., Gupte, A., Jordan, R., Jheeta, B. S., Ladha, K., Nazir, M., Pal, R., Patel, R. P., McManus, R., Singal, A., Saunders, P., Syed, A. B., Bahal, A., Dau, H., Walker, D. M., McNeilly, R., Bolidai, A., MacCarthy, N., Lawton, D., Vardhani, M., Sengupta, G., Kinloch, D., Howie, F., Serrano-Garcia, A., Paget, S. E., Till, R., Seal, P., Morrell, J., Maxwell, T., Singh, G., Warden, D., Elias, R., Dixon, C., Pandey, R. K., Challenor, V., Davies, S., Gibbs, M., Gillet, A., Goldie, C., Jarvis, I., Johnson, P., Malden, M., Moore, J., Morton, C., Nehrig, K., Sheringham, P., Wilson, G., Halcox, J., O'Connor, I., Ling, K., Edwards, D., Charles, H., Weatherup, A., Davies, E., Watkins, N., Morgan, D., Davies, R., Lindsay, A., Beacock, D., Balai, R., Kirmond, P., Brindle, P., Bundy, C., Cahill, T., Dayani, A., Eavis, P., Mohr, S., Hayne, S., Krasucki, C., Micheals, M., Orpen, I., Parker, I., Sewell, R., Sharp, D., Smith, A., Stevens, A., Upton, J., Victory, J., Wernham, C., Davis, R., Mays, C., Andrews, M., Takhar, J., Travill, C., Choudhury, P., Matta, W., Ihonor, A., O'Dong, C., Rahman, S., Singer, P., Gillam, S., Bath, P. S., Razzaq, N., O'Toole, O., Rowe, P., Williams, H., Allcock, A., Tucker, A., Sprott, V., Kyd, K., Cunliffe, G., Arden, C., Bateman, A., Kassianos, G., Sinclair, D., Turner, C., Jagathesan, R., Sattar, F., Ashford, A., Chukwu, A., Taylor, H., Pradhan, R., Rundell, T., Howlett, R., Bietzk, R., Myint, M., Partington, M., O'Reilly, F., Baverstock, M., Dixon, S., Tennekoon, M., Brand, N., Haimes, P., Keller, P., Whetstone, S., Kovyrshyna, O., Rogozhyna, V., Kiver, T., Vasylenko, V., Kucheryava, L., Salimova, S., Alekseenko, V., Gukov, O., Myhailiv, I., Kardashevskaya, L., Prikolota, O., Bashkirtcev, O., Andreev, E., Tkachenko, L., Mospan, M., Batushkin, V., Safonova, L., Ogorodnichuk, A., Pustovit, S., Romanov, S., Burlakova, L., Voloshko, Y., Lafarenko, V., Vlasuk, Z., Leshchuk, O., Chushak, S., Koval, V., Stasuk, O., Pogrebna, O., Kornienko, S., Tikhonova, S., Fesenko, T., Kuzmina, T., Ushakov, O., Vechtomova, N., Potapska, L., Illushechkin, I., Kryvenkova, E., Lysunets, O., Tsygankov, O., Bardachenko, L., Voloshyna, L., Ginzburg, V., Franskyavichene, L., Korotich, T., Vyshnevaya, N., Bilous, N., Kulinich, S., Kulik, V., Sadykova, I., Berezhna, T., Molotyagina, S., Pham, M. H., Pham, H. T., Khong, N. H., K. B., Do, T. B., Le, P. A., Do, T. C., Do, Nguyen, N. Q., Q. H., Do, K. C., Vu, Pham, N. H., Pham, T. H. T., M. C., Ta, Phan, D. P., Nguyen, T. T. H., Pham, T. T. N., T. L., To, V. T., Le, Dang, L., Bui, L., Pham, T. T. H., Phan, H. H., Bui, T. T. H., Tuong, T. V. A., Nguyen, T. P., Nguyen, T. H., Nguyen, B. K., D. B., Vu, Pham, N. S., T. Q., Do, Pham, T. S., Dang, V. D., D. T., Le, V. C., Do, Nguyen, T. K. L., Luong, H. D., Luu, T. Q., Pham, N. V., Huynh, T. K., N. T. H., Tu, Ngo, K. A., Nguyen, T. T. C., Ong, T. T. L., Doan, V. B., Kim, T. B., T. N., Vo, Tran, T. T. T., Nguyen, T. A., Tran, V. D., Nguyen, A. K., Tran, A. C., Ngo, M. H., N. H., Vu, I. T., Ly, Tran, N. P. H., Tran, L. U. P., Nguyen, T. N., Tran, T. H., Truong, P. H., Mai, T. L., Hoang, V. S., Bui, C. M. A., Dang, V. P., Truong, Q. B., M. P., Vo, Nguyen, V. T., Chau, N. H., T. T. H., Ta, Dinh, H. N., Tran, H., Nguyen, H. K. N., Chung, A., Chung, E., Martina-Hooi, B., Angela, R., Ramoutar, P., Fillet, R., Tilluckdharry, R., Dookie, T., Foster, E., Hart, C., Omardeen, F., Ramphall, S., Lalla, C., Cheng, J., Elliott, V., Falconer, H., Hurlock-Clarke, L., Ishmael, R., Lalljie, G., Lee, K., Liqui-Lung, A., Massay, R., Mohammed, H., Brown, C., Daniel, R., Didier, M., Salas, Z., CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), University of Glasgow, Maria Cecilia Hospital [Cotignola], Royal Brompton Hospital, Montreal Heart Institute Coordinating Centre (MHICC), Université de Montréal (UdeM), Medical University of Silesia (SUM), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Dorogoichenko, Aleksandra, Laucevičius, Aleksandras, Jurgaitienė, Rūta, Šlapikas, Rimvydas, Barauskienė, Gražina, Jankauskienė, Edita, Revienė, Sigita, Vaišvila, Tautvydas, Zaronskienė, Danutė, Šlapikienė, Ona Birutė, Kupstytė, Nora, Rinkūnienė, Egidija, Steponėnienė, Rima Vitalija, Kojelienė, Jūratė, Badarienė, Jolita, Dženkevičiūtė, Vilma, Sadauskienė, Eglė, Butkuvienė, Irena, Stankevičius, R., Paliulionienė, R., Snikytė, R., Mažutavičius, R., and CLARIFY Investigators
- Subjects
Male ,Genetics and Molecular Biology (all) ,Heart disease ,medicine.medical_treatment ,atrial fibrillation ,coronary ,anticoagulants ,patients ,atrial flutter ,lcsh:Medicine ,Coronary Artery Disease ,Practice Patterns ,030204 cardiovascular system & hematology ,Chest pain ,Biochemistry ,[SHS]Humanities and Social Sciences ,Cohort Studies ,Coronary artery disease ,Angina ,0302 clinical medicine ,Aged ,Anticoagulants ,Atrial Fibrillation ,Drug Therapy, Combination ,Female ,Guideline Adherence ,Humans ,Outpatients ,Platelet Aggregation Inhibitors ,Practice Patterns, Physicians' ,Registries ,Practice Patterns, Physicians'/statistics & numerical data ,030212 general & internal medicine ,Myocardial infarction ,lcsh:Science ,Stroke ,Anticoagulants/administration & dosage ,Multidisciplinary ,Medicine (all) ,Atrial fibrillation ,Guideline Adherence/statistics & numerical data ,3. Good health ,Combination ,Cardiology ,[SHS] Humanities and Social Sciences ,medicine.symptom ,Research Article ,medicine.medical_specialty ,Coronary Artery Disease/drug therapy ,Agricultural and Biological Sciences (all) ,Biochemistry, Genetics and Molecular Biology (all) ,NO ,03 medical and health sciences ,Drug Therapy ,Internal medicine ,medicine ,Platelet Aggregation Inhibitors/administration & dosage ,Physicians' ,Atrial Fibrillation/drug therapy ,business.industry ,lcsh:R ,Percutaneous coronary intervention ,Outpatients/statistics & numerical data ,medicine.disease ,lcsh:Q ,Human medicine ,business - Abstract
BACKGROUND: Few data are available regarding the use of antithrombotic strategies in coronary artery disease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the prevalence of AF and its antithrombotic management in a contemporary population of patients with stable coronary artery disease.METHODS AND FINDINGS: CLARIFY is an international, prospective, longitudinal registry of outpatients with stable coronary artery disease, defined as prior (≥12 months) myocardial infarction, revascularization procedure, coronary stenosis >50%, or chest pain associated with evidence of myocardial ischemia. Overall, 33,428 patients were screened, of whom 32,954 had data available for analysis at baseline; of these 2,229 (6.7%) had a history of AF. Median (interquartile range) CHA2DS2-VASc score was 4 (3, 5). Oral anticoagulation alone was used in 25.7%, antiplatelet therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%. OAC use was independently associated with permanent AF (pCONCLUSIONS: In this contemporary cohort of patients with stable coronary artery disease and AF, most of whom are theoretical candidates for anticoagulation, oral anticoagulants were used in only 47.2%. Half of the patients received antiplatelet therapy alone and one-fifth received both antiplatelets and oral anticoagulants. Efforts are needed to improve adherence to guidelines in these patients.TRIAL REGISTRATION: ISRCTN registry of clinical trials: ISRCTN43070564.
- Published
- 2015
- Full Text
- View/download PDF
9. Persistent atrial fibrillation worsen heart rate variabilità, activity and heart rate, as shown by a continuous minitoring by implantable biventricular pacemakers in heart failure patients. Poster Heart Rhythm 2007, 28th Annual Scientific Session of the Heart Rhythm Society
- Author
-
Padeletti L, Pugliei A, Gasparini M, Lunati M, Sassara M, Lanolina M, Orazi S, Botto GL, Coltella A, Valsecchi S, Piro F., BORIANI, GIUSEPPE, Padeletti L, Pugliei A, Gasparini M, Lunati M, Sassara M, Lanolina M, Orazi S, Botto GL, Boriani G, Coltella A, Valsecchi S, and Piro F
- Published
- 2007
10. Persistent atrial fibrillation worsen heart rate variabilità, activity and heart rate, as shown by a continuous minitoring by implantable biventricular pacemakers in heart failure patients
- Author
-
Padeletti L, Puglisi A, Gasparini M, Lunati M, Sassara M, Lanolina M, Orazi S, Botto GL, Coltella A, Valsecchi S, Piro, BORIANI, GIUSEPPE, Padeletti L, Puglisi A, Gasparini M, Lunati M, Sassara M, Lanolina M, Orazi S, Botto GL, Boriani G, Coltella A, Valsecchi S, and Piro
- Subjects
ATRIAL FIBRILLATION ,HEART FAILURE ,BIVENTRICULAR PACING ,MONITORING - Published
- 2007
11. Impact of mitral regurgitation on the outcome of patients treated with CRT-D: Data from the InSync ICD Italian registry
- Author
-
Giuseppe, Boriani, M. D., H. D., P, Maurizio, Gasparini, † MAURIZIO LANDOLINA, ‡ MAURIZIO LUNATI, MAURO BIFFI, Massimo, Santini, LUIGI PADELETTI, Giulio, Molon, †† GIANLUCA BOTTO, ‡‡ TIZIANA DE SANTO, B. S., and SERGIO VALSECCHI, Gasparini, M., Galimberti, P., Regoli, F., Ceriotti, C., Istituto Clinico Humanitas, Rozzano-, Milano, Lunati, M., Cattafi, G., Magenta, G., Paolucci, M., Vecchi, R., Niguarda, Hospital, Milano, Santini, M., Ricci, R., San Filippo Neri, Roma, Gaita, F., Bocchiardo, M., Didonna, P., Caponi, D., Civile, Hospital, Asti, Tavazzi, L., Landolina, M., Rordorf, R., Petracci, B., Vicentini, A., Savastano, S., Matteo, Pol. S., Pavia, Padeletti, L., Pieragnoli, P., Careggi, Firenze, Vincenti, A., Deceglia, S., Cir ` o, A., Gerardo Dei Tintori, S., Monza(MI), Curnis, A., Mascioli, G., Spedali, Civili, Brescia, Puglisi, A., Bianchi, S., Peraldo, C., Fatebenefratelli, Roma, Sassara, M., Achilli, A., Turreni, F., Rossi, P., Belcolle, Hospital, Viterbo, Perego, Gb., Luca Auxologico, S., Ravazzi, P. A., Diotallevi, P., Antonio e Biagio, Ss., Alessandria, Tritto, M., Mater, Domini, Castellanza, (VA), Carboni, A., Ardissino, D., Gonzi, G., Serra, V., Civile, Parma, Vergara, G., Maria Del Carmine, S., Rovereto, (TN), Boriani, G., Biffi, M., Martignani, C., Diemberger, I., Orsola-Mailpighi, S., Bologna, Luzzi, G., Policlinico, Bari, Laurenzi, F., Camillo, S., Pistis, G., Mauriziano, Torino, Cesario, A., Grassi, G. B., Ostia, (RM), Zanotto, G., Civile, Verona, Orazi, S., Rieti, Ometto, R., Bonanno, C., Bortolo, S., Vicenza, Molon, G., Barbieri, E., Cuore, S., Negrar, (VR), Raviele, A., Gasparini, G., Umbertoi, Mestre, (VE), Botto, G., Luzi, M., Sagone, A., Anna, S., Como, Vado, A., Croce, S., Cuneo, Montenero, A., Multimedica, Giovanni (MI), Sestos., Inama, G., Maggiore, Crema, Sassone, B., Civile, Bentivoglio, (BO), Briedda, M., Zardo, F., Maria, S., Pordenone, E. Bertaglia, Mirano (VE), Proclemer, A., Udine, Zanon, F., Civile, Rovigo, Disertori, M., Gramegna, L., Delgreco, M., Dallafior, D., Chiara, S., Trento, Tomasi, C., Maresta, A., Piancastelli, M., Maria Croci, S., Ravenna, Bridda, A., Martino, S., Belluno, Mantovan, R., C`afoncello, Treviso, Fusco, A., Pederzoli, Peschiera, (VR), Baraldi, P., Agostino, S., Modena, G. Lonardi, Legnago (VR), Rahue, W., Maurizio, S., Bolzano, P. Delise, Conegliano (TV), Menozzi, C., Marianuova, S., Reggioemilia, Babudri, P., Borgoroma, Verona, Marconi, R., Mazzoni, Ascolipiceno, Alfano, G. DeFabrizio F., Moscati, G., Avellino, Barbato, G., Maggiore, Bologna, P. Gelmini, Desenzano (BS), Disabato, Leopoldo, S., Merate, (LC), Ricci, S., Ramazzini, Carpi, (MO), Aulerio, M. D., Biagio, S., Domodossola, (VB), Morgagni, G. L., Latini, R., Macerata, Bardelli, G., Fornaroli, Magenta, (MI), R. Paulichl, F. Tappeiner Merano (BZ), Bernasconi, M., Marzegalli, M., Carlo, S., Neri, G., Montebelluna, Treviso, E. Occhetta, Novara, Bocconcelli, P., Salvatore, S., Pesaro, A. Capucci, Piacenza, Campana, A., Giovanni, S., Salerno, N. Dibelardino, Velletri (RM), Vaglio, A., Giovanni, e Paolo, Venezi, A., Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M, Padeletti L, Molon G, Botto G, de Santo T, Valsecchi S, and InSync/InSync ICD Italian Registry Investigators.
- Subjects
Male ,Mitral Valve Insufficiency ,Socio-culturale ,heart failure ,Comorbidity ,CARDIAC RESYNCHRONIZATION THERAPY ,mitral regurgitation ,Risk Assessment ,Survival Analysis ,Survival Rate ,Treatment Outcome ,Italy ,Risk Factors ,Prevalence ,Humans ,Female ,Registries ,Aged - Abstract
We assessed the influence of clinically significant mitral regurgitation (MR) on clinical-echocardiographic response and outcome in heart failure (HF) patients treated with a biventricular defibrillator (cardiac resynchronization therapy defibrillator [CRT-D]). METHODS AND RESULTS: A total of 659 HF patients underwent successful implantation of CRT-D and were enrolled in a multicenter prospective registry (median follow-up of 15 months). Following baseline echocardiographic evaluation, patients were stratified into two groups according to the severity of MR: 232 patients with more than mild MR (Group MR+: grade 2, 3, and 4 MR) versus 427 patients with mild (grade 1) or no functional MR (Group MR-). On 6- and 12-month echocardiographic evaluation, MR was seen to have improved in the vast majority of MR+ patients, while it remained unchanged in most MR- patients. On 12-month follow-up evaluation, a comparable response to CRT was observed in the two groups, in terms of the extent of left ventricular reverse remodeling and combined clinical and echocardiographic response. During long-term follow-up, event-free survival did not differ between MR+ and MR- patients, even when subpopulations of patients with ischemic heart disease and with dilated cardiomyopathy were analyzed separately. On multivariate analysis, the only independent predictor of death from any cause was the lack of β-blocker use. CONCLUSIONS: This observational analysis supports the use of CRT-D in HF patients with clinically significant MR; MR had no major influence on patient outcome.
- Published
- 2012
12. Improve Energy Efficiency in Manufacturing Plants through Consumption Forecasting and Real Time Control: Case Study from Pharmaceutical Sector
- Author
-
Cesarotti, V, Introna, V, and Deli Orazi, S
- Subjects
energy consumption targeting and control ,energy management ,energy efficiency, energy management ,Settore ING-IND/17 - Impianti Industriali Meccanici ,energy efficiency - Published
- 2010
13. Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry
- Author
-
Boriani, G, Gasparini, M, Landolina, M, Lunati, M, Biffi, M, Santini, M, Padeletti, L, Molon, G, Botto, G, De Santo, T, Valsecchi, S, Galimberti, P, Regoli, F, Ceriotti, C, Cattafi, G, Magenta, G, Paolucci, M, Vecchi, R, Ricci, R, Gaita, F, Bocchiardo, M, Didonna, P, Caponi, D, Tavazzi, L, Rordorf, R, Petracci, B, Vicentini, A, Savastano, S, Matteo, Ps, Pieragnoli, P, Vincenti, A, Deceglia, S, Ciró, A, Gerardo Dei Tintori, S, Curnis, A, Mascioli, G, Puglisi, A, Bianchi, S, Peraldo, C, Sassara, M, Achilli, A, Turreni, F, Rossi, P, Perego, Gb, Ravazzi, Pa, Diotallevi, P, Antonio, e Biagio SS, Tritto, M, Carboni, A, Ardissino, D, Gonzi, G, Serra, V, Vergara, G, Maria Del Carmine, S, Martignani, C, Frabetti, L, Orsola-Mailpighi, S, Luzzi, G, Laurenzi, F, Camillo, S, Pistis, G, Cesario, A, Grassi, Gb, Zanotto, G, Orazi, S, Ometto, R, Bonanno, C, Bortolo, S, Barbieri, E, Cuore, S, Raviele, A, Gasparini, G, Luzi, M, Sagone, A, Anna, S, Vado, A, Croce, S, Montenero, A, Giovanni, Ss, Inama, G, Sassone, B, Briedda, M, Zardo, F, Maria, S, Bertaglia, E, Proclemer, A, Zanon, F, Disertori, M, Gramegna, L, Delgreco, M, Dallafior, D, Chiara, S, Tomasi, C, Maresta, A, Piancastelli, M, Maria Croci, S, Bridda, A, Martino, S, Mantovan, R, Fusco, A, Baraldi, P, Agostino, S, Lonardi, G, Rahue, W, Maurizio, S, Delise, P, Menozzi, C, Marianuova, S, Babudri, P, Marconi, R, Defabrizio, G, Alfano, F, Moscati, G, Barbato, G, Gelmini, P, Disabato, Leopoldo, S, Ricci, S, Aulerio, Md, Biagio, S, Morgagni, Gl, Latini, R, Bardelli, G, Paulichl, R, Tappeiner Merano, F, Bernasconi, M, Marzegalli, M, Carlo, S, Neri, G, Occhetta, E, Bocconcelli, P, Salvatore, S, Capucci, A, Campana, A, Giovanni, S, Dibelardino, N, Vaglio, A, Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M, Padeletti L, Molon G, Botto G, De Santo T, and Valsecchi S
- Subjects
Cardiomyopathy, Dilated ,Male ,medicine.medical_specialty ,Pacemaker, Artificial ,medicine.medical_treatment ,Cardiac resynchronization therapy ,Cardiomyopathy ,Heart Valve Diseases ,Myocardial Ischemia ,Socio-culturale ,Heart failure ,Aged ,Atrial Fibrillation ,Defibrillators, Implantable ,Female ,Heart Failure ,Humans ,Middle Aged ,Registries ,Treatment Outcome ,Ventricular Remodeling ,Cardiac Pacing, Artificial ,Clinical Research ,Internal medicine ,medicine ,cardiovascular diseases ,Remodelling ,Valvular heart disease ,Heart transplantation ,Ejection fraction ,business.industry ,valvular heart disease ,Atrial fibrillation ,Dilated cardiomyopathy ,medicine.disease ,Cardiology ,cardiovascular system ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims To analyse the effectiveness of cardiac resynchronization therapy (CRT) in patients with valvular heart disease (a subset not specifically investigated in randomized controlled trials) in comparison with ischaemic heart disease or dilated cardiomyopathy patients. Methods and results Patients enrolled in a national registry were evaluated during a median follow-up of 16 months after CRT implant. Patients with valvular heart disease treated with CRT ( n = 108) in comparison with ischaemic heart disease ( n = 737) and dilated cardiomyopathy ( n = 635) patients presented: (i) a higher prevalence of chronic atrial fibrillation, with atrioventricular node ablation performed in around half of the cases; (ii) a similar clinical and echocardiographic profile at baseline; (iii) a similar improvement of LVEF and a similar reduction in ventricular volumes at 6–12 months; (iv) a favourable clinical response at 12 months with an improvement of the clinical composite score similar to that occurring in patients with dilated cardiomyopathy and more pronounced than that observed in patients with ischaemic heart disease; (v) a long-term outcome, in term of freedom from death or heart transplantation, similar to patients affected by ischaemic heart disease and basically more severe than that of patients affected by dilated cardiomyopathy. Conclusion In ‘real world’ clinical practice, CRT appears to be effective also in patients with valvular heart disease. However, in this group of patients the outcome after CRT does not precisely overlap any of the two other groups of patients, for which much more data are currently available.
- Published
- 2009
14. Follow-up of CRT-ICD: implications for the use of remote follow-up systems. Data from the InSync ICD italian Registry
- Author
-
Lunati, M, Gasparini, M, Santini, M, Landolina, M, Perego, Gb, Pappone, C, Galimberti, P, Regoli, F, Gronda, E, Cattafi, G, Magenta, G, Paolucci, M, Vecchi, R, Ricci, R, Gaita, F, Bocchiardo, M, Didonna, P, Caponi, D, Tavazzi, L, Rordorf, R, Petracci, B, Vicentini, A, Deceglia, S, Cirò, A, Curnis, A, Mascioli, G, Puglisi, A, Bianchi, S, Sassara, M, Achilli, A, Turreni, F, Rossi, P, B Perego, G, A Ravazzi, P, Diotallevi, P, Tritto, M, Carboni, A, Ardissino, D, Gonzi, G, Serra, V, Vergara, G, Boriani, G, Biffi, M, Martignani, C, Frabetti, L, Orsola, S, Luzzi, G, Laurenzi, F, Pistis, G, Cesario, A, Zanotto, G, Orazi, S, Ometto, R, Bonanno, G, Molon, G, Barbieri, E, Raviele, A, Gasparini, G, Botto, G, Luzi, M, Sagone, A, Vado, A, Montenero, A, Inama, G, Sassone, B, Briedda, M, Zardo, F, Bertaglia, E, Proclemer, A, Zanon, F, Disertori, M, Gramegna, L, Delgreco, M, Dallafior, D, Tomasi, C, Maresta, A, Piancastelli, M, Bridda, A, Mantovan, R, Fusco, A, Baraldi, P, Lonardi, G, Rahue, W, Delise, P, Menozzi, C, Babudri, P, Marconi, R, De Fabrizio, F Alfano, Moscati, G, Barbato, G, Gelmini, P, Disabato, Ricci, S, D Aulerio, M, L Morgagni, G, Latini, R, Bardelli, G, Paulichl, R, Bernasconi, M, Marzegalli, M, Vicedomini, G, Augello, G, Paglino, G, Neri, G, Occhetta, E, Bocconcelli, P, Capucci, A, Campana, A, Dibelardino, N, and Vaglio, A
- Subjects
Socio-culturale - Published
- 2008
15. Reproducibility of electrocardiographic findings in patients with suspected reflex neurally-mediated syncope
- Author
-
Brignole, M, Sutton, R, Menozzi, C, Moya, A, Garcia-Civera, R, G Benditt, D, Vardas, P, Wieling, W, Andresen, D, Migliorini, R, Hollinworth, D, Grovale, N, Zanna, F, P Lopez, M, Mohammad, S, Guthmann, A, Manders, M, D Van Aggel, Erckens, D, Andersen, V, Sousani, E, Eppacher, C, J St Ores, T De Santo, Bottoni, N, Ammirati, F, Santini, M, Donateo, P, Reviele, A, Giada, F, Orazi, S, Alboni, P, Dinelli, M, Perego, G, Brambilla, R, A Del Rosso, Vincenti, A, S De Ceglia, Sassone, B, T Baratto, M, Ungar, A, Currò, S, Gulizia, M, Francese, M, Pandolfo, L, Burattini, M, Cornacchia, D, Casali, E, Giani, P, Santangelo, L, Panico, S, G De Marchi, Marchetti, A, Buja, G, Folino, F, Spampinato, A, Bruni, G, Lunati, M, Buttera, G, García-Civera, R, Morell, S, Ruiz, R, Sanjuan, R, F Garcia-Sacristan, J, Beiras, X, Campos, G, Alonso, C, Garcia-Alberola, A, Lacuna, J, P Villacastín, J, Castellanos, P, Roda, J, Palanca, V, Martí, J, Delclós, J, Alvarez, M, Tercedor, L, Castellanos, E, Mauri, T, F Lozano, I, Tomás, J, Bènèzet, J, Fidalgo, M, G Martinez, J, Herreros, B, Muñoz, F, A J, J Aerts, L V, A Boersma, M Schroeder-Tanka, J, R Van Mechelen, H Ruiter, J, Ehlers, C, Meinerts, T, Schuchert, A, Vieth, T, Reithmann, C, P Von Lowis, Cripps, T, Sulke, N, A Kenny, R, D Skehan, J, Paul, V, Wrigley, M, E Louridas, G, Vasilikos, V, N Jakobsen, T, H Simonsen, E, B Johansen, J, W Grander Affiliation, ACS - Amsterdam Cardiovascular Sciences, and General Internal Medicine
- Subjects
Male ,medicine.medical_specialty ,Socio-culturale ,Neurological disorder ,Ventricular tachycardia ,Electrocardiography ,Internal medicine ,medicine ,Syncope, Vasovagal ,Humans ,Sinus rhythm ,Prospective Studies ,cardiovascular diseases ,Asystole ,Prospective cohort study ,medicine.diagnostic_test ,biology ,business.industry ,Syncope (genus) ,Reproducibility of Results ,Middle Aged ,medicine.disease ,biology.organism_classification ,Electrocardiographic Finding ,Anesthesia ,Cardiology ,cardiovascular system ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
The reproducibility of electrocardiographic (ECG) recordings in syncopal recurrences and the diagnostic role of nonsyncopal arrhythmias are not well known. The objective of this study was to analyse the reproducibility of the ECG findings recorded with implantable loop recorders in 41 patients with suspected neurally-mediated syncope who were included in the International Study on Syncope of Uncertain Origin-2 study and that had > or =2 events recorded by implantable loop recorders. In these patients, the electrocardiogram obtained with the first documented syncope (index syncope) was compared with other recorded events. Twenty-two patients had > or =2 syncopes, and their electrocardiograms were reproducible in 21 (95%): 15 with sinus rhythm, 5 with asystole, and 1 with ventricular tachycardia; 1 had asystole at first syncope and sinus rhythm at recurrent syncope. In 32 patients with nonsyncopal episodes, an arrhythmia was documented in 9, and all of them had the same arrhythmia during the index syncope (100% reproducibility); conversely, when sinus rhythm was documented (23 patients) during nonsyncopal episodes, an arrhythmia was still documented in 6 during the index syncope (70% reproducibility; p = 0.0004). In conclusion, the ECG findings during the first syncope are highly reproducible in subsequent syncopes. The presence of an arrhythmia during nonsyncopal episodes is also highly predictive of the mechanism of syncope, but the presence of sinus rhythm does not rule out the possibility of arrhythmia during syncope. Therefore the finding of an arrhythmia during a nonsyncopal episode allows the etiologic diagnosis of syncope, and eventually to anticipate treatment, without waiting for syncope
- Published
- 2008
16. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors.
- Author
-
Laurenzi F, Achilli A, Avella A, Peraldo C, Orazi S, Perego GB, Cesario A, Valsecchi S, DE Santo T, Puglisi A, and Tondo C
- Abstract
Background: There are few studies on cardiac resynchronization therapy (CRT) in heart failure (HF) patients with preexisting right ventricular (RV) pacing. The purpose of this study was to determine the efficacy of CRT upgrading in RV-paced patients and the predictivity of electromechanical dyssynchrony parameters (EDP) evaluated by standard echocardiography (ECHO) and tissue Doppler imaging (TDI). Methods: Thirty-eight consecutive patients with HF [New York Heart Association (NYHA) class III or IV, LVEF < 35%], prior continuous RV pacing, and absence of atrial fibrillation were enrolled in the presence of a paced QRS >/= 150 ms and evaluated by ECHO and TDI. A responder was defined as a patient with a favorable change in NYHA class and neither HF hospitalization nor death, plus an absolute increase of LVEF >/= 10 units. Results: At six-months follow-up, the whole study population had significant improvement in symptoms, systolic function, and QRS duration (P < 0.001); 32 (84%) patients had a favorable clinical outcome, 25 (66%) were considered responders according to the previous definition. Postimplant QRS was similarly reduced in both responders and nonresponders, whereas EDP had a significant improvement only in responders (P < 0.05). Using EDP, 23 (79%) patients were responders compared with 2 (22%) patients without mechanical dyssynchrony (P = 0.002). Conclusions: In HF patients with previous RV pacing, CRT is effective to improve clinical, functional outcome, and LV performance and to reduce electromechanical dyssynchrony in a large proportion of patients. Dyssynchrony evaluated by standard and TDI ECHO can be useful for CRT selection of paced patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
17. The influence of electrical-atmospheric alterations on man
- Author
-
Pantaleoni, G. C., Murri, A., Fanini, Donatella, Palumbo, G., De Berardinis, G., Del Gusto, G., and Orazi, S.
- Published
- 1984
18. 754 Device-based CRT optimization by peak endocardial acceleration in cardiac resynchronisation therapy
- Author
-
Naegele, H., Delnoy, P.P., Ritter, P., Padeletti, L., Orazi, S., Anselme, F., Renesto, F., and Magagnin, V.
- Subjects
THERAPEUTICS ,HEART diseases - Abstract
An abstract of the study "Device-Based CRT Optimization by Peak Endocardial Acceleration in Cardiac Resynchronization Therapy," by H. Naegele and colleagues is presented.
- Published
- 2007
- Full Text
- View/download PDF
19. Prediction of response to cardiac resynchronization therapy: the selection of candidates for CRT (SCART) study.
- Author
-
Achilli A, Peraldo C, Sassara M, Orazi S, Bianchi S, Laurenzi F, Donati R, Perego GB, Spampinato A, Valsecchi S, Denaro A, Puglisi A, and SCART Study Investigators
- Abstract
Background: The aim of this study was to evaluate the ability of baseline clinical and echocardiographic parameters to predict a positive response to CRT. Methods: We analyzed 6-month data from the first 133 consecutive patients enrolled in a multicenter prospective study. These patients had symptomatic heart failure (HF) refractory to pharmacological therapy (NYHA class II-IV), left ventricular ejection fraction (LVEF) <=35%, and prespecified electrocardiographic, echocardiographic or tissue Doppler imaging markers of left ventricular (LV) dyssynchrony. Results: After a follow-up period of 6 months, 1 patient died and 13 were hospitalized for worsening HF. There were significant (P < 0.01) clinical, functional, and echocardiographic improvements that included: New York heart Association Class, Quality-of-Life Score, QRS duration, LVEF, LV end-diastolic and end-systolic diameter (LVESD), and severity of mitral regurgitation A positive response was documented in 90/133 (68%) patients who presented an improved clinical composite score associated to an increase in LVEF >= 5 units. A multivariate analysis identified that a smaller LVESD (OR = 0.957, 95% CI 0.920-0.996; P = 0.030) and longer interventricular mechanical delay (IVMD) (OR = 1.017, 95% CI 1.005-1.029, P = 0.007) as independent predictors of a positive response. Receiver-operating curve analysis showed that a positive response to CRT may be predicted in patients with IVMD > 44 ms (with a sensitivity of 66% and a specificity of 55%) or with LVESD < 60 mm (with a sensitivity of 66% and a specificity of 61%). Conclusions: Our results confirm the limited value of QRS duration in the selection of patients for CRT. A less-advanced stage of disease and echocardiographic evidence of interventricular dyssynchrony demonstrated to predict response to CRT, while intraventricular dyssynchrony did not predict response. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
20. CP02: MYOCARDIAL PERFORMANCE EVALUATION AFTER RV APICAL PACING: THE “WHERE” STUDY.
- Author
-
Padeletti, L., Santini, M., Ravazzi, A., Orazi, S., Bellocci, F., and Biscionef, F.
- Abstract
BACKGROUND RV apical pacing has been shown to decrease LV performance, which can be assessed either by Echo or by a pacing system equipped with a microaccelerometer (Sorin Biomedica, Italy) able to measure Peak Endocardial Acceleration, PEA, and therefore to evaluate LVdP/dtmax. AIM This multicentre (26 European Centres), prospective, randomised, crossover, single-blind study compares, intra-patient, LV function in 2 different settings of DDDR programmation: maintained spontaneous AV conduction or RV pacing at Optimized AV Delay (OAVD). METHODS 103pts (67M, 73.1±9.1yrs) were implanted with a Sorin BEST-Living System for SSS, sinus bradycardia, with QRS<120ms, PR<220ms.After 1 month (baseline) pacemakers were randomly programmed for 2 successive periods of 6 months either pacing interval with OAVD or in spontaneous AV conduction. Group1 began with 6mos pacing; group2 with 6mos of spontaneous conduction. Echo and PEA assessments and Quality of Life (QOL) evaluation were performed (in spontaneous AV conditions) at baseline, crossover and at the end of the 2nd period. RESULTS 87pts completed the study with similar baseline values. LVEDD:47.8±5.4 (Group1-41pts) and 47.9±5.8 (Group2-46pts); PEA:0.93±0.5 (Group1) and 0.96±0.52 (Group2) (p=ns). Both in Group1 and Group2 LVEDD increased during pacing period (from 47.8±5.4 to 50.4±5.5 and from 44.9±5.7 to 47.7±6.5 respectively; p<0.05) and decrease during spontaneous conduction (from 50.4±5.5 to 46.4±5.8 and from 47.9±5.8 to 44.9±5.7 respectively; p<0.05). PEA values for both Group1 and Group 2 decreased during pacing period (from 0.93±0.5 to 0.73±0.5 and from 1.20±0.64 to 0.95±0.54 respectively; p<0.05) and increased during spontaneous conduction (from 0.73±0.5 to 1.10±0.56 and from 0.96±0.52 to 1.20±0.64 respectively; p<0.05). CONCLUSIONS 1)Echo/PEA data confirm that RV apical decreases LV performance (contractility) [ABSTRACT FROM PUBLISHER]
- Published
- 2005
- Full Text
- View/download PDF
21. 2. Bradyarrhythmias, Sick Sinus Syndrome & Carotid Sinus Syndrome.
- Author
-
Orazi, S., Pieragnoli, P., Ravazzi, P., Diotallevi, P., Baldi, N., Russo, V., Occhetta, E., Gostoli, E., Di Biase, L., and Padeletti, L.
- Abstract
The multicenter SA&AF study prospectively evaluated patients (Pts) with SSS and paroxysmal atrial fibrillation (PAF) to test the hypothesis that sleep apnea (SA) may worsen the arrhythmic scenario.Methods 72 pts (36 M, 77±6 yrs) were enrolled and implanted with a pacemaker Selection 9000 (Vitatron). After one month for diagnostics and therapies optimization, Pts were followed-up for 4 months. SA Group was diagnosed according to at least 2 criteria of the Berlin Questionnaire, already validated for this purpose. Remaining Pts were the control Group. Results 20 Pts (28%, 75±7 years) were in SA Group and 52 (72%, 78±6 years) in control Group. Both were equivalent for sex, age and body mass index. 18/20 Pts in SA Group (90%) and 23/52 in control Group (44%) had hypertension (p=0.0004). Both Groups did not show any statistically significant difference for AF episodes/month (7±13 vs. 36±122) and AF burden (0.3±0.6 vs. 2.0±4.8). The daily distribution of AF episodes/month did not show any statistically significant difference in the 2 groups. Conclusions In Pts paced for SSS and documented PAF, SA does not worsen AF scenario. [ABSTRACT FROM PUBLISHER]
- Published
- 2005
22. 711 Prognostic value of noninvasive permanent pacemaker stress echocardiography.
- Author
-
Chubuchny, V., Varga, A., Guarracini, L., Baldini, U., Orazi, S., Perticucci, R., Coppola, V., Agrusta, M., Mottola, G., and Picano, E.
- Subjects
STRESS echocardiography ,PROGNOSIS ,CARDIAC pacemakers - Abstract
An abstract of the article "Prognostic Value of Noninvasive Permanent Pacemaker Stress Echocardiography" by V. Chubuchny and colleagues is presented.
- Published
- 2003
- Full Text
- View/download PDF
23. P-501 Preliminary results of pitagora study show a clinical improvement in patients affected by sick sinus syndrome and treated by DDDRP pacing.
- Author
-
Gulizia, M., Mangiameli, S., Indelicato, V., Butera, G., Evola, R., Circo, A., Vasco, C., Di Girolamo, A., Orazi, S., Battaglia, A., and Grammatico, A.
- Published
- 2002
24. 17.7 A pragmatic approach for a safe programming of biventricular stimulators: Preliminary data of a prospective study.
- Author
-
Orazi, S., Evangelista, F., Menè, A., Romeo, F., Venturini, D., and Riva, U.
- Published
- 2002
25. 7.8 Tolerability of atrial fibrillation (AF) prevention algorithms.
- Author
-
Cervellati, D., Propato, N., Mambelli, M., Tartagni, F., Ricci, S., Pignatd, F., Melandri, F., Fontana, P., Orazi, S., Mené, A., Reggiani, A., and Pepi, P.
- Published
- 2002
26. Cardiac output (CO) impairment by excessive heart rate (HR) increase in pacemaker (PM) implanted patients (PTS).
- Author
-
Orazi, S., Bellagamba, L., Mascia, F., Fattore, L., Pandolfi, M., Severini, D., Palumbo, B., Di Mauro, M., and Corbucci, G.
- Published
- 2000
27. Closed loop stimulation versus peak endocardial acceleration. clinical evaluation of two contractility based pacing systems.
- Author
-
Orazi, S., Ravazzi, A.P., Diotallevi, P., Ciceroni, C., De Sanctis, A., and Audoglio, R.
- Published
- 2000
28. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial
- Author
-
Francesco Lisi, Giuseppe Boriani, Andrea Grammatico, S. Mangiameli, Nicolò Di Giovanni, Ludovico Vasquez, Michele Massimo Gulizia, Serafino Orazi, Giacomo Chiarandà, Guglielmo Piccione, Orazio Pensabene, Andrea Colletti, Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, Di Giovanni N, Colletti A, Pensabene O, Lisi F, Vasquez L, Grammatico A, and Boriani G
- Subjects
Male ,medicine.medical_treatment ,Amiodarone ,Propafenone ,law.invention ,Electrocardiography ,Randomized controlled trial ,law ,Reference Values ,Atrial Fibrillation ,80 and over ,Single-Blind Method ,Prospective Studies ,Sinus ,Aged, 80 and over ,Flecainide ,medicine.diagnostic_test ,Sotalol ,Statistics ,Cardiac Pacing, Artificial ,Aged ,Anti-Arrhythmia Agents ,Arrhythmia, Sinus ,Dose-Response Relationship, Drug ,Drug Administration Schedule ,Drug Therapy, Combination ,Female ,Follow-Up Studies ,Humans ,Probability ,Risk Assessment ,Statistics, Nonparametric ,Survival Rate ,Treatment Outcome ,Atrial fibrillation ,Anesthesia ,Artificial ,Combination ,Cardiology ,Drug ,Cardiology and Cardiovascular Medicine ,Arrhythmia ,medicine.drug ,medicine.medical_specialty ,Randomization ,Antiarrhythmic agent ,Dose-Response Relationship ,Drug Therapy ,Internal medicine ,medicine ,Nonparametric ,business.industry ,medicine.disease ,Cardiac Pacing ,business - Abstract
BACKGROUND: Rhythm control is an important goal in the treatment of recurrent atrial tachyarrhythmias (AT). The PITAGORA study was a randomized trial in patients paced for sinus node disease (SND), designed to test the noninferiority of class IC antiarrhythmic drugs (AADs) to amiodarone in terms of a primary end point composed of death, permanent AT, cardiovascular hospitalization, atrial cardioversion, or AAD change. METHODS: Randomization was stratified to assign 2 patients to amiodarone and 2 patients to class IC AADs: propafenone or flecainide. One hundred seventy-six patients (46% men, 72 +/- 8 years) were enrolled. Device diagnostics continuously monitored AT recurrences and duration. RESULTS: In a mean follow-up of 20 +/- 9 months, the primary end point occurred in 23 (30.7%) of 75 class IC patients and in 28 (40.0%) of 70 amiodarone patients. The absolute difference in the end point incidence (-9.3%; 95% CI between 3.7% and -22.3%) confirmed the noninferiority of class IC to amiodarone (P = .007). Kaplan-Meier 1-year freedom from AT episodes >10 minutes, 1 day, and 7 days was 40%, 73%, and 91% for amiodarone and 28%, 78%, and 86% for class IC AADs (P = nonsignificant). CONCLUSIONS: In patients paced for SND and suffering from AT, class IC AADs proved not to be inferior to amiodarone in terms of the primary composite end point described or end points which were differently composed of mortality, efficacy, or AAD side effects. The AADs studied also showed similar results in terms of symptoms, quality of life, and freedom from AT recurrences.
- Published
- 2008
29. A randomised comparison between Ramp and Burst+ atrial antytachycardia pacing therapies in patients suffering from bradycardia and atrial fibrillation and implanted with a DDDRP device
- Author
-
BORIANI, GIUSEPPE, O. Pensabene, S. Mangiameli, N. Di Giovanni, A. Colletti, C. Puntrello, G. Scardace, M. Gulizia, Gulizia M, Mangiameli S, Orazi S, Chiaranda’ G, Boriani G, Piccione G, Puntrello C, Scardace G, G. Boriani, O. Pensabene, S. Mangiameli, N. Di Giovanni, A. Colletti, C. Puntrello, G. Scardace, and M. Gulizia
- Published
- 2005
30. Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence.
- Author
-
Orazi S, Boffa A, Salerno M, Angelelli L, Zaffagnini S, and Filardo G
- Abstract
Purpose: The association of adipose tissue-derived injectable products with platelet-rich plasma (PRP) has been promoted for osteoarthritis (OA) treatment. The aim of this study was to investigate the preclinical and clinical evidence supporting the potential of this combined approach to treat OA., Methods: A systematic review was performed in January 2024 on five databases (PubMed, Embase, Scopus, Cochrane, and Web-of-Science) to identify preclinical in vivo and clinical studies. Safety, OA biomarker changes, and outcomes in terms of clinical and imaging results were analyzed. The quality of studies was assessed with the SYRCLE's tool for preclinical studies and the Downs and Black checklist for clinical studies., Results: Ten preclinical studies (223 animals) and 14 clinical studies (594 patients) were included. Preclinical results documented improvements at the cartilage histological and immunohistochemical evaluation and at the biomarkers level. Clinical studies confirmed the procedure's safety, and the case series suggested satisfactory results in different joints in terms of symptoms and function improvement, with positive findings at the biomarker level. However, the randomized controlled trials did not document any clinical benefit, nor any changes in the imaging analysis. A large heterogeneity and overall poor quality were documented in both preclinical and clinical studies., Conclusions: There is an increasing interest in the use of adipose tissue-derived injectable products associated with PRP for the treatment of OA joints, with preclinical studies showing promising results with this combined approach. However, clinical studies did not confirm the benefits offered by PRP augmentation to adipose tissue-derived injectable products in patients affected by OA.
- Published
- 2024
- Full Text
- View/download PDF
31. Leukocytes Do Not Influence the Safety and Efficacy of Platelet-Rich Plasma Injections for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Controlled Trial.
- Author
-
Romandini I, Boffa A, Di Martino A, Andriolo L, Cenacchi A, Sangiorgi E, Orazi S, Pizzuti V, Zaffagnini S, and Filardo G
- Subjects
- Humans, Double-Blind Method, Male, Female, Middle Aged, Aged, Injections, Intra-Articular, Pain Measurement, Treatment Outcome, Platelet-Rich Plasma, Osteoarthritis, Knee therapy, Leukocytes
- Abstract
Background: Platelet-rich plasma (PRP) is increasingly used for the injection treatment of knee osteoarthritis (OA). However, the role of leukocytes contained in PRP is controversial, with some preclinical studies suggesting detrimental effects and others emphasizing their contribution in secreting bioactive molecules., Purpose: To compare the safety and effectiveness of leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP) for the treatment of knee OA., Hypothesis: That leukocytes could influence results both in terms of adverse events and clinical outcomes., Study Design: Randomized controlled trial; Level of evidence, 1., Methods: This double-blind randomized controlled trial included 132 patients with Kellgren-Lawrence grade 1-3 knee OA who were randomized to a 3-injection cycle of either LR-PRP or LP-PRP. Patients were prospectively assessed at baseline and at 2, 6, and 12 months with subjective evaluations comprising the International Knee Documentation Committee (IKDC) subjective score, the KOOS (Knee injury and Osteoarthritis Outcome Score), the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), the visual analog scale for pain, the EuroQol-visual analog scale, the EuroQol-5 dimensions, and the Tegner activity scale. Objective evaluations consisted of the IKDC objective score, active/passive range of motion, and circumference of the index and contralateral knees. Patient judgment of the treatment was recorded as well as adverse reactions and failures., Results: An overall improvement in subjective and objective outcomes was documented, with no differences between the 2 groups, except for the improvement in the IKDC subjective score at 2 months, which was greater for the LR-PRP group compared with the LP-PRP group (14.8 ± 14.8 vs 8.6 ± 13.3, respectively; P = .046), as well as for active ( P = .021) and passive ( P = .040) ROM of the index knee at 6 months, showing statistically significant higher values in the LP-PRP group; and for quadriceps circumference of the index ( P = .042) and contralateral ( P = .045) knees at 12 months, which were significantly greater in the LR-PRP group. The IKDC subjective score improved from 42.5 ± 17.6 at baseline to 55.6 ± 21.4 at 12 months for the LR-PRP group ( P < .0005) and from 45.7 ± 16.4 to 55.3 ± 20.4 for the LP-PRP group ( P = .001). No differences in terms of patient treatment judgment were observed at all follow-up time points. No severe adverse events related to the treatment were reported, but some mild adverse events related to the treatment were observed: 16 in the LR-PRP group and 17 in the LP-PRP group. Treatment failed in 5 patients in the LR-PRP group and 2 in the LP-PRP group., Conclusion: This double-blind randomized controlled trial demonstrated that leukocytes did not affect the safety and efficacy of intra-articular PRP injections for the treatment of patients with knee OA. Both LR-PRP and LP-PRP demonstrated comparable clinical outcomes at all follow-up time points, without showing differences in subjective and objective outcomes or in adverse events and treatment failures., Registration: NCT04187183 (ClinicalTrials.gov)., Competing Interests: One or more of the authors has declared the following potential conflict of interest or source of funding: S.Z. has received institutional support from Fidia Farmaceutici, CartiHeal, IGEA Clinical Biophysics, Biomet, and Kensey Nash; grant support from I+; and royalties from Springer outside the submitted work. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.
- Published
- 2024
- Full Text
- View/download PDF
32. Single-plug osteochondral autograft transplantation for knee osteochondritis dissecans: Clinical improvement and long-term survivorship at a minimum ten year follow-up.
- Author
-
Orazi S, Andriolo L, Franceschini M, Di Martino A, Zaffagnini S, and Filardo G
- Subjects
- Humans, Male, Female, Adult, Follow-Up Studies, Young Adult, Adolescent, Treatment Outcome, Bone Transplantation methods, Cartilage, Articular surgery, Prospective Studies, Autografts, Patient Satisfaction, Osteochondritis Dissecans surgery, Knee Joint surgery, Transplantation, Autologous methods
- Abstract
Purpose: Osteochondritis dissecans (OCD) can lead to detrimental effects in the affected joints. Osteochondral autologous transplantation (OAT) allows to restore the articular surface with an autologous osteochondral unit. While short-term results are documented, there is a lack of long-term data. Aim of this study was to analyze the long-term clinical results of single-plug OAT for the treatment of knee OCD., Methods: Twenty patients (14 men, 6 women) were treated with single plug-OAT. Mean age was 23.6 ± 9.9 years and BMI was 23.3 ± 3.6 kg/m
2 . Lesion size was 2.3 ± 1.6 cm2 and defects included 14 medial femoral condyles (MFC) and 6 lateral femoral condyles (LFC). Patients were followed up prospectively at baseline, 24 months, 60 months, and at minimum ten years (12.6 ± 2.0 years) using the IKDC subjective score and through an overall judgment on treatment satisfaction. The activity level was evaluated with the Tegner score and adverse events and failures were also recorded. Factors influencing the clinical outcomes, including age, sex, BMI, lesions size, and lesion location were also investigated., Results: No severe adverse events and no surgical failures were reported and 85.0% of patients were satisfied at a minimum ten year follow-up. Subjective IKDC showed a significant and stable improvement at all follow-ups, passing from 45.3 ± 16.5 at baseline to 73.7 ± 16.6 at 24 months (p < 0.0005), to 72.9 ± 16.6 at 60 months (p < 0.0005), and to 74.1 ± 20.8 at long-term follow-up (p < 0.0005). Patients with OCD lesions localized on the LFC obtained lower results compared to those with MFC lesions at two years and five years (p = 0.034 and p = 0.023). The highest long-term scores were obtained in patients with lesion size lower than 2 cm2 (89.1 ± 8.8) compared to patients with lesion size between 2 and 4 cm2 (69.2 ± 15.7), and patients with lesion size larger than 4 cm2 (63.8 ± 34.6)., Conclusions: OAT is a suitable technique to treat knee OCD in young patients and offers a high patient satisfaction and a significant improvement in terms of clinical subjective scores, with results remaining stable over time, although without reaching the pre-injury activity level. No severe adverse events and no surgical failures have been documented confirming OAT as a valid treatment option, although the best long-term results for lesions smaller than 2 cm2 and for MFC lesions should be considered when choosing this procedure to address knee OCD lesions., (© 2024. The Author(s) under exclusive licence to SICOT aisbl.)- Published
- 2024
- Full Text
- View/download PDF
33. Knee temperature remains abnormal in patients successfully treated with anterior cruciate ligament reconstruction: An infrared thermography analysis.
- Author
-
De Marziani L, Orazi S, Boffa A, Andriolo L, Di Martino A, Zaffagnini S, and Filardo G
- Abstract
Purpose: The aim of this study was to evaluate if the operated knee environment remains abnormal in patients successfully treated with anterior cruciate ligament reconstruction (ACL-R)., Methods: Thirty asymptomatic patients were enrolled (28 men, 2 women, age 28.6 ± 6.54 years, body mass index: 24.9 ± 3.0 kg/m
2 ) and evaluated at 42.2 ± 12.5 months after surgery. Patients were assessed with patient-reported outcome measurements and with a triaxial accelerometer. The temperature of the knees as well as four regions of interest were evaluated with an infrared thermographic camera FLIR T1020 (FLIR® Systems) according to a standardised protocol including a baseline evaluation and further evaluations immediately after exercise and after 5, 10 and 20 min. The temperature of the ACL-R knee was compared to that of the contralateral healthy knee for the purpose of the study., Results: The mean temperature of the knee was higher ( p = 0.010) for the ACL-R knees (31.4 ± 1.4°C) compared to the healthy knees (31.1 ± 1.6°C), as well as for the patellar area ( p = 0.005), the lateral area ( p = 0.016) and the medial area ( p = 0.014). The analysis of the response to the exercises of the ACL-R knees showed similar trends to the healthy knees but higher temperature values at all time points ( p < 0.05). Patients who underwent ACL-R with concomitant meniscal treatment showed higher knee temperatures compared to ACL-R knees without concomitant meniscal treatment after 5 ( p = 0.047), 10 ( p = 0.027) and 20 min ( p = 0.048)., Conclusions: The temperature of asymptomatic knees previously treated with ACL-R is higher than the contralateral healthy knee, both at rest and after exercise, with a further increase in knees that underwent both ACL-R and meniscal treatment. These results suggest an inflammatory state persisting years after the surgery, which could predispose to the early onset of knee degeneration., Level of Evidence: III, Case-control study., Competing Interests: Stefano Zaffagnini reports non‐financial support from personal fees from I+SRL and grants from Fidia Farmaceutici SPA, Cartiheal Ltd., IGEA clinical biophysics, BIOMET and Kensey Nash outside the submitted work. The funders had no role in the design of the study; in the collection, analyses or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results. The other authors declare no conflict of interest., (© 2024 The Author(s). Journal of Experimental Orthopaedics published by John Wiley & Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.)- Published
- 2024
- Full Text
- View/download PDF
34. Joint Response to Exercise Is Affected by Knee Osteoarthritis: An Infrared Thermography Analysis.
- Author
-
De Marziani L, Boffa A, Orazi S, Andriolo L, Di Martino A, Zaffagnini S, and Filardo G
- Abstract
Infrared thermography can be used to evaluate the inflammation characterizing the joint environment of OA knees, but there is limited evidence on the response to physical exercise. Identifying the response to exercise of OA knees and the influencing variables could provide important information to better profile patients with different knee OA patterns. Sixty consecutive patients (38 men/22 women, 61.4 ± 9.2 years) with symptomatic knee OA were enrolled. Patients were evaluated with a standardized protocol using a thermographic camera (FLIR-T1020) positioned at 1 m with image acquisition of an anterior view at baseline, immediately after, and at 5 min after a 2-min knee flexion-extension exercise with a 2 kg anklet. Patients' demographic and clinical characteristics were documented and correlated with the thermographic changes. This study demonstrated that the temperature response to exercise in symptomatic knee OA was affected by some demographic and clinical characteristics of the assessed patients. Patients with a poor clinical knee status presented with a lower response to exercise, and women showed a greater temperature decrease than men. Not all evaluated ROIs showed the same trend, which underlines the need to specifically study the different joint subareas to identify the inflammatory component and joint response while investigating knee OA patterns.
- Published
- 2023
- Full Text
- View/download PDF
35. The nucleoplasmic interactions among Lamin A/C-pRB-LAP2α-E2F1 are modulated by dexamethasone.
- Author
-
Ricci A, Orazi S, Biancucci F, Magnani M, and Menotta M
- Subjects
- Ataxia Telangiectasia drug therapy, Ataxia Telangiectasia genetics, DNA-Binding Proteins genetics, E2F1 Transcription Factor genetics, Fibroblasts drug effects, Fibroblasts metabolism, Humans, Lamin Type A genetics, Membrane Proteins genetics, Nuclear Envelope drug effects, Nuclear Envelope genetics, Protein Binding drug effects, Salivary Proline-Rich Proteins genetics, Ataxia Telangiectasia metabolism, DNA-Binding Proteins metabolism, Dexamethasone pharmacology, E2F1 Transcription Factor metabolism, Lamin Type A metabolism, Membrane Proteins metabolism, Nuclear Envelope metabolism, Salivary Proline-Rich Proteins metabolism
- Abstract
Ataxia telangiectasia (AT) is a rare genetic neurodegenerative disease. To date, there is no available cure for the illness, but the use of glucocorticoids has been shown to alleviate the neurological symptoms associated with AT. While studying the effects of dexamethasone (dex) in AT fibroblasts, by chance we observed that the nucleoplasmic Lamin A/C was affected by the drug. In addition to the structural roles of A-type lamins, Lamin A/C has been shown to play a role in the regulation of gene expression and cell cycle progression, and alterations in the LMNA gene is cause of human diseases called laminopathies. Dex was found to improve the nucleoplasmic accumulation of soluble Lamin A/C and was capable of managing the large chromatin Lamin A/C scaffolds contained complex, thus regulating epigenetics in treated cells. In addition, dex modified the interactions of Lamin A/C with its direct partners lamin associated polypeptide (LAP) 2a, Retinoblastoma 1 (pRB) and E2F Transcription Factor 1 (E2F1), regulating local gene expression dependent on E2F1. These effects were differentially observed in both AT and wild type (WT) cells. To our knowledge, this is the first reported evidence of the role of dex in Lamin A/C dynamics in AT cells, and may represent a new area of research regarding the effects of glucocorticoids on AT. Moreover, future investigations could also be extended to healthy subjects or to other pathologies such as laminopathies since glucocorticoids may have other important effects in these contexts as well.
- Published
- 2021
- Full Text
- View/download PDF
36. Proteomics and transcriptomics analyses of ataxia telangiectasia cells treated with Dexamethasone.
- Author
-
Menotta M, Orazi S, Gioacchini AM, Spapperi C, Ricci A, Chessa L, and Magnani M
- Subjects
- Blotting, Western, Cell Line, Gene Expression Profiling, Gene Expression Regulation drug effects, Humans, Microarray Analysis, Proteomics, Ataxia Telangiectasia drug therapy, Ataxia Telangiectasia metabolism, Dexamethasone pharmacology, Glucocorticoids pharmacology, Proteome drug effects, Transcriptome drug effects
- Abstract
Ataxia telangiectasia (A-T) is an incurable and rare hereditary syndrome. In recent times, treatment with glucocorticoid analogues has been shown to improve the neurological symptoms that characterize this condition, but the molecular mechanism of action of these analogues remains unknown. Hence, the aim of this study was to gain insight into the molecular mechanism of action of glucocorticoid analogues in the treatment of A-T by investigating the role of Dexamethasone (Dexa) in A-T lymphoblastoid cell lines. We used 2DE and tandem MS to identify proteins that were influenced by the drug in A-T cells but not in healthy cells. Thirty-four proteins were defined out of a total of 746±63. Transcriptome analysis was performed by microarray and showed the differential expression of 599 A-T and 362 wild type (WT) genes and a healthy un-matching between protein abundance and the corresponding gene expression variation. The proteomic and transcriptomic profiles allowed the network pathway analysis to pinpoint the biological and molecular functions affected by Dexamethasone in Dexa-treated cells. The present integrated study provides evidence of the molecular mechanism of action of Dexamethasone in an A-T cellular model but also the broader effects of the drug in other tested cell lines.
- Published
- 2018
- Full Text
- View/download PDF
37. In vivo effects of dexamethasone on blood gene expression in ataxia telangiectasia.
- Author
-
Menotta M, Biagiotti S, Orazi S, Rossi L, Chessa L, Leuzzi V, D'Agnano D, Plebani A, Soresina A, and Magnani M
- Subjects
- Adolescent, Child, Female, Humans, Male, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Ataxia Telangiectasia blood, Ataxia Telangiectasia drug therapy, Dexamethasone administration & dosage, Gene Expression Regulation drug effects
- Abstract
Ataxia telangiectasia (AT) is a rare incurable genetic disease caused by biallelic mutations in the Ataxia telangiectasia-mutated gene. Intra-erythrocyte infusion of dexamethasone improves clinical outcomes in AT patients; however, the molecular mechanisms that lead to this improvement remain unknown. Hence, to gain a better understanding of these mechanisms, we assessed the effects of glucocorticoid administration on gene expression in the blood of AT patients. Whole blood was obtained from nine children enrolled in a phase two clinical trial, who were being treated with dexamethasone (AT Dexa), from six untreated AT patients (AT) and from six healthy volunteers (WT). CodeLink Whole Genome Bioarrays were used to assess transcript expression. The reliability of the differentially expressed genes (DEGs) was verified by qRT-PCR analysis. The enriched Gene Ontology (GO) terms and the pathways of the Kyoto Encyclopedia of Genes and Genomes (KEGG) of DEGs obtained by group comparisons were achieved using the Database for Annotation, Visualization and Integrated Discovery (DAVID). Functional network analyses were computed by Reactome FI. The likely involved transcription factors were revealed by iRegulon. Among the identified DEGs influenced by the pathology and restored by dexamethasone, we detected 522 upregulated probes coding for known proteins, while 22 probes were downregulated, as they were in healthy subjects. These results provide useful information and represent a first step towards gaining a better understanding of the underlying mechanisms of the effects of dexamethasone on AT patients.
- Published
- 2018
- Full Text
- View/download PDF
38. ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T.
- Author
-
Menotta M, Biagiotti S, Spapperi C, Orazi S, Rossi L, Chessa L, Leuzzi V, D'Agnano D, Soresina A, Micheli R, and Magnani M
- Subjects
- Adolescent, Ataxia Telangiectasia Mutated Proteins genetics, Biomarkers, Child, Dexamethasone administration & dosage, Female, Glucocorticoids administration & dosage, Glucocorticoids therapeutic use, Humans, Leukocytes, Mononuclear metabolism, Male, Ataxia Telangiectasia drug therapy, Ataxia Telangiectasia metabolism, Ataxia Telangiectasia Mutated Proteins metabolism, Dexamethasone therapeutic use, Gene Expression Regulation drug effects, Protein Isoforms metabolism
- Abstract
Background: Ataxia Telangiectasia (AT) is a rare incurable genetic disease, caused by biallelic mutations in the Ataxia Telangiectasia-Mutated (ATM) gene. Treatment with glucocorticoid analogues has been shown to improve the neurological symptoms that characterize this syndrome. Nevertheless, the molecular mechanism underlying the glucocorticoid action in AT patients is not yet understood. Recently, we have demonstrated that Dexamethasone treatment may partly restore ATM activity in AT lymphoblastoid cells by a new ATM transcript, namely ATMdexa1., Results: In the present study, the new ATMdexa1 transcript was also identified in vivo, specifically in the PMBCs of AT patients treated with intra-erythrocyte Dexamethasone (EryDex). In these patients it was also possible to isolate new "ATMdexa1 variants" originating from canonical and non-canonical splicing, each containing the coding sequence for the ATM kinase domain. The expression of the ATMdexa1 transcript family was directly related to treatment and higher expression levels of the transcript in patients' blood correlated with a positive response to Dexamethasone therapy. Neither untreated AT patients nor untreated healthy volunteers possessed detectable levels of the transcripts. ATMdexa1 transcript expression was found to be elevated 8 days after the drug infusion, while it decreased 21 days after treatment., Conclusions: For the first time, the expression of ATM splicing variants, similar to those previously observed in vitro, has been found in the PBMCs of patients treated with EryDex. These findings show a correlation between the expression of ATMdexa1 transcripts and the clinical response to low dose dexamethasone administration.
- Published
- 2017
- Full Text
- View/download PDF
39. Nano-Mechanical Characterization of Ataxia Telangiectasia Cells Treated with Dexamethasone.
- Author
-
Menotta M, Biagiotti S, Bartolini G, Marzia B, Orazi S, Germani A, Chessa L, and Magnani M
- Subjects
- Cell Line, Cell Nucleus Shape drug effects, Cell Shape drug effects, Elastic Modulus, Humans, Microscopy, Atomic Force, Tubulin metabolism, Ataxia Telangiectasia pathology, Dexamethasone pharmacology, Glucocorticoids pharmacology
- Abstract
Ataxia telangiectasia is a rare genetic disease and no therapy is currently available. Glucocorticoid analogues have been shown to improve the neurological symptoms of treated patients. In the present study ataxia telangiectasia and wild type cells were used as a cellular model and treated with dexamethasone. The cells were subsequently investigated for membrane and whole cell mechanical properties by atomic force microscopy. In addition, cytoskeleton protein dynamics and nuclear shapes were assayed by fluorescence microscopy, while western blots were used to assess actin and tubulin content. At the macro level, dexamethasone directly modified the cell shape, Young's modulus and cytoskeleton protein dynamics. At the nano level, the roughness of the cell surface and the local nano-mechanical proprieties were found to be affected by Dexa. Our results show that ataxia telangiectasia and wild type cells are affected by Dexa, although there are dissimilarities in some macro-level and nano-level features between the tested cell lines. The Young's modulus of the cells appears to depend mainly on nuclear shape, with a slight contribution from the tested cytoskeleton proteins. The current study proposes that dexamethasone influences ataxia telangiectasia cell membranes contents, cell components and cell shape.
- Published
- 2017
- Full Text
- View/download PDF
40. Dexamethasone improves redox state in ataxia telangiectasia cells by promoting an NRF2-mediated antioxidant response.
- Author
-
Biagiotti S, Menotta M, Orazi S, Spapperi C, Brundu S, Fraternale A, Bianchi M, Rossi L, Chessa L, and Magnani M
- Subjects
- Ataxia Telangiectasia genetics, Ataxia Telangiectasia metabolism, Ataxia Telangiectasia prevention & control, Ataxia Telangiectasia Mutated Proteins genetics, Ataxia Telangiectasia Mutated Proteins metabolism, Blotting, Western, Cell Line, Transformed, Cells, Cultured, Fibroblasts drug effects, Fibroblasts metabolism, Gene Expression drug effects, Glucocorticoids pharmacology, Glucosephosphate Dehydrogenase metabolism, Humans, Lymphocytes drug effects, Lymphocytes metabolism, Microscopy, Fluorescence, Mutation, NF-E2-Related Factor 2 genetics, Oxidation-Reduction drug effects, Reactive Oxygen Species metabolism, Reverse Transcriptase Polymerase Chain Reaction, Antioxidants metabolism, Dexamethasone pharmacology, Glutathione metabolism, NADP metabolism, NF-E2-Related Factor 2 metabolism
- Abstract
Ataxia telangiectasia (A-T) is a rare incurable neurodegenerative disease caused by biallelic mutations in the gene for ataxia-telangiectasia mutated (ATM). The lack of a functional ATM kinase leads to a pleiotropic phenotype, and oxidative stress is considered to have a crucial role in the complex physiopathology. Recently, steroids have been shown to reduce the neurological symptoms of the disease, although the molecular mechanism of this effect is largely unknown. In the present study, we have demonstrated that dexamethasone treatment of A-T lymphoblastoid cells increases the content of two of the most abundant antioxidants [glutathione (GSH) and NADPH] by up to 30%. Dexamethasone promoted the nuclear accumulation of the transcription factor nuclear factor (erythroid-derived 2)-like 2 to drive expression of antioxidant pathways involved in GSH synthesis and NADPH production. The latter effect was via glucose 6-phosphate dehydrogenase activation, as confirmed by increased enzyme activity and enhancement of the pentose phosphate pathway rate. This evidence indicates that glucocorticoids are able to potentiate antioxidant defenses to counteract oxidative stress in ataxia telangiectasia, and also reveals an unexpected role for dexamethasone in redox homeostasis and cellular antioxidant activity., (© 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2016
- Full Text
- View/download PDF
41. Long-term monitoring of respiratory rate in patients with heart failure: the Multiparametric Heart Failure Evaluation in Implantable Cardioverter-Defibrillator Patients (MULTITUDE-HF) study.
- Author
-
Forleo GB, Santini L, Campoli M, Malavasi M, Scaccia A, Menichelli M, Riva U, Lamberti F, Carreras G, Orazi S, Ribatti V, Di Biase L, Lovecchio M, Natale A, Valsecchi S, and Romeo F
- Subjects
- Aged, Female, Humans, Male, Prospective Studies, Sensitivity and Specificity, Defibrillators, Implantable, Heart Failure physiopathology, Monitoring, Physiologic instrumentation, Respiratory Rate physiology
- Abstract
Background: Monitoring respiratory rate (RR) is recommended at the time of hospital presentation for acute decompensation in heart failure (HF). Device-based continuous monitoring of RR may be helpful for diagnostic and prognostic stratification after implantable cardioverter-defibrillator (ICD) implantation. This study was undertaken to analyze short- and long-term changes in ICD-measured RR and to relate RR with the patient's clinical status and the occurrence of HF events., Methods: One hundred twenty-four consecutive HF patients who received ICD endowed with this diagnostic capability (Boston Scientific Inc., Natick, MA, USA) were prospectively enrolled. Patients were followed up for 12 months., Results: At the baseline, the proportion of New York Heart Association (NYHA) class III-IV was higher among patients with daily maximum RR >27 breaths/min (third tertile) than those with <24 breaths/min (first tertile) (43 vs. 23%, p < 0.05). Moreover, the ejection fraction was lower (27 ± 7 vs. 34 ± 8%, p < 0.05). In patients with HF hospitalizations (33 events) and urgent visits for HF (15 events), the weekly average of RR calculated over the 7 days preceding hospital accesses did not differ from values recorded at the baseline and before scheduled follow-up visits. However, the weekly variation in RR (i.e., the difference between maximum and minimum values collected over the week) was significantly higher prior to hospitalization (p < 0.05). A weekly variation >3 breaths/min in maximum RR predicted an impending hospital admission for HF with sensitivity of 73 % and specificity of 57%., Conclusions: In this study, elevated values of ICD-monitored RR identified patients with worse functional status and lower systolic function. The weekly variation in RR increased before HF exacerbation. This monitoring technology may represent a useful tool in the clinical management of patients with HF.
- Published
- 2015
- Full Text
- View/download PDF
42. Ventricular Rate Stabilization In Patients With Permanent Atrial Fibrillation And Single-Chamber Ventricular Pacemaker: RARE-PEARL Study.
- Author
-
Occhetta E, Mazzocca G, Svetlich C, Scipione P, Fabiani A, Giammaria M, Orazi S, and Corbucci G
- Abstract
Background: In patients with permanent atrial fibrillation (AF) rate irregularity can cause symptoms and impair the pumping function of the heart. Ventricular pacing at a rate close to the mean spontaneous ventricular rate can result in a more stable ventricular rate. Specific algorithms for automatic Ventricular Rate Stabilization (VRS) were designed and implemented in commercially available pacemakers. To assess this dynamic rate control we designed the RARE-PEARL study: prospective, randomized, cross-over, double-blinded. Methods: Patients with permanent AF, symptomatic episodes of brady-tachycardia, left ventricular ejection fraction (LVEF) >40%, NYHA class I/II/III, were eligible for enrolment. Each patient (n = 67) was implanted with a single-chamber VVIR pacemaker (models C20 or T20, Vitatron BV, The Netherlands) equipped with the VRS algorithm. At the end of a four week stabilization period, patients were randomized to VRS algorithm ON or OFF (2 months) and then crossed-over for the second phase (2 months). Primary endpoint was patient's preference. Results: Sixty six patients ended the study: 19 (29%) had no preference; 15 (23%) preferred algorithm OFF, 32 (48%) algorithm ON (p<0.0001, algorithm ON vs OFF). In 58% of patients the algorithm ON caused an increase of ventricular pacing percentage > 10%. The ventricular pacing percentage was 82±10% with algorithm ON vs 59±26% with algorithm OFF (p<0.0001). Symptoms did not differ significantly. Conclusions: The VRS algorithm significantly increases the ventricular pacing percentage in patients with permanent AF. This pacing function is preferred by the majority of patients implanted with a single-chamber VVIR pacemaker.
- Published
- 2014
- Full Text
- View/download PDF
43. Association between frequent cardiac resynchronization therapy optimization and long-term clinical response: a post hoc analysis of the Clinical Evaluation on Advanced Resynchronization (CLEAR) pilot study.
- Author
-
Delnoy PP, Ritter P, Naegele H, Orazi S, Szwed H, Zupan I, Goscinska-Bis K, Anselme F, Martino M, and Padeletti L
- Subjects
- Age Distribution, Aged, Female, Humans, Longitudinal Studies, Male, Netherlands epidemiology, Pilot Projects, Prognosis, Risk Factors, Sex Distribution, Survival Rate, Treatment Outcome, Cardiac Resynchronization Therapy mortality, Cardiac Resynchronization Therapy statistics & numerical data, Heart Failure mortality, Heart Failure prevention & control
- Abstract
Aims: The long-term clinical value of the optimization of atrioventricular (AVD) and interventricular (VVD) delays in cardiac resynchronization therapy (CRT) remains controversial. We studied retrospectively the association between the frequency of AVD and VVD optimization and 1-year clinical outcomes in the 199 CRT patients who completed the Clinical Evaluation on Advanced Resynchronization study., Methods and Results: From the 199 patients assigned to CRT-pacemaker (CRT-P) (New York Heart Association, NYHA, class III/IV, left ventricular ejection fraction <35%), two groups were retrospectively composed a posteriori on the basis of the frequency of their AVD and VVD optimization: Group 1 (n = 66) was composed of patients 'systematically' optimized at implant, at 3 and 6 months; Group 2 (n = 133) was composed of all other patients optimized 'non-systematically' (less than three times) during the 1 year study. The primary endpoint was a composite of all-cause mortality, heart failure-related hospitalization, NYHA functional class, and Quality of Life score, at 1 year. Systematic CRT optimization was associated with a higher percentage of improved patients based on the composite endpoint (85% in Group 1 vs. 61% in Group 2, P < 0.001), with fewer deaths (3% in Group 1 vs. 14% in Group 2, P = 0.014) and fewer hospitalizations (8% in Group 1 vs. 23% in Group 2, P = 0.007), at 1 year., Conclusion: These results further suggest that AVD and VVD frequent optimization (at implant, at 3 and 6 months) is associated with improved long-term clinical response in CRT-P patients.
- Published
- 2013
- Full Text
- View/download PDF
44. Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of unexplained origin: the PRESS study.
- Author
-
Santini M, Castro A, Giada F, Ricci R, Inama G, Gaggioli G, Calò L, Orazi S, Viscusi M, Chiodi L, Bartoletti A, Foglia-Manzillo G, Ammirati F, Loricchio ML, Pedrinazzi C, Turreni F, Gasparini G, Accardi F, Raciti G, and Raviele A
- Subjects
- Aged, Aged, 80 and over, Cardiac Pacing, Artificial adverse effects, Cardiac Pacing, Artificial mortality, Equipment Design, Female, Heart Block complications, Heart Block diagnosis, Heart Block mortality, Heart Block physiopathology, Humans, Italy, Kaplan-Meier Estimate, Male, Pacemaker, Artificial, Proportional Hazards Models, Prospective Studies, Single-Blind Method, Syncope diagnosis, Syncope etiology, Syncope mortality, Syncope physiopathology, Time Factors, Treatment Outcome, Cardiac Pacing, Artificial methods, Heart Block therapy, Syncope prevention & control
- Abstract
Background: Syncope in patients with bifascicular block (BFB) is a common event whose causes might be difficult to assess., Methods and Results: Prevention of syncope through permanent cardiac pacing in patients with bifascicular block (PRESS) is a multicenter, prospective, randomized, single-blinded study designed to demonstrate a reduction in symptomatic events in patients with bifascicular block and syncope of undetermined origin implanted with permanent pacemaker. Device programming mode (NASPE/BPEG code) at DDD with a lower rate of 60 ppm is compared with backup pacing at DDI with a lower rate of 30 ppm. The end point consisted of (1) syncope, (2) symptomatic presyncopal episodes associated with a device intervention (ventricular pacing), and (3) symptomatic episodes associated with intermittent or permanent atrioventricular block (any degree). One hundred one patients were enrolled and randomized. Primary end point events at 2 years were observed in 23 patients, with a significant lower incidence in the study group (hazard ratio, 0.32; 95% confidence interval [CI], 0.10-0.96; P=0.042). Reduction of any symptoms, associated or not with device intervention, was superior in DDD60 compared with DDI30 (hazard ratio, 0.4; 95% confidence interval, 0.25-0.78; P=0.0053). Fourteen patients developed other rhythm diseases and met class I indication for pacing. The annual incidence of rhythm disease development was 7.4%., Conclusions: In patients with bifascicular block and syncope of undetermined origin, the use of a dual chamber pacemaker programmed to DDD60 led to a significant reduction of syncope or symptomatic events associated with a cardioinhibitory origin, compared with DDI30 programming. Symptoms associated with a new onset of rhythm disease were found in 15% of the population at 2 years.
- Published
- 2013
- Full Text
- View/download PDF
45. Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: results of the CAMI-GUIDE study.
- Author
-
Biasucci LM, Bellocci F, Landolina M, Rordorf R, Vado A, Menardi E, Giubilato G, Orazi S, Sassara M, Castro A, Massa R, Kheir A, Zaccone G, Klersy C, Accardi F, and Crea F
- Subjects
- Aged, Biomarkers metabolism, Epidemiologic Methods, Female, Humans, Male, Middle Aged, Myocardial Infarction mortality, Tachycardia, Ventricular blood, Tachycardia, Ventricular mortality, C-Reactive Protein metabolism, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Myocardial Infarction blood, Tachycardia, Ventricular therapy
- Abstract
Aims: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear., Methods and Results: The primary objective of the CAMI-GUIDE study is to assess the predictive role of C-reactive protein for SCD or VT/VF in ischaemic patients with the ejection fraction <30% and ICDs. Secondary endpoints included all-cause mortality, hospitalizations, and death from heart failure. Additional analyses incorporated cystatin-C and NT-ProBNP in multi-marker approach for the prediction of adverse outcomes. A total of 300 patients were enrolled. All-cause mortality at 2 years was 22.6%, mortality from heart failure was 8.3%. Primary endpoint occurred in 17.3%. At a competing risk multivariable analysis adjusted for baseline variables, no significant difference in primary endpoint was found between patients with C-reactive protein ≤3 vs. >3 mg/L [heart rate (HR) 0.91 (0.50-1.64) P = 0.76], while C-reactive protein >3 mg/L was strongly associated with mortality due to heart failure [HR: 3.17 (1.54-6.54) P = 0.002]. NT-proBNP above median was significantly associated with the primary endpoint [adjusted HR: 1.46 (1.020-2.129) P = 0.042]. A risk function, including the three biomarkers, NYHA class and resting HR, allowed stratification of patient mortality risk from 5 to 50%., Conclusion: C-reactive protein >3 mg/L is not associated with SCD or fast VT/VF, however, is a strong predictor of HF mortality. Biomarkers combined with clinical markers allow an excellent risk stratification of mortality at 2 years.
- Published
- 2012
- Full Text
- View/download PDF
46. Performance of a ventricular automatic-capture algorithm in a wide clinical setting.
- Author
-
Pecora D, Morandi F, Liccardo M, Pepi P, Orazi S, Caico SI, Scaccia A, Bizeau O, Citerne O, Raciti G, and Del Giudice G
- Subjects
- Aged, Diagnosis, Computer-Assisted statistics & numerical data, Female, Humans, Italy epidemiology, Male, Therapy, Computer-Assisted statistics & numerical data, Algorithms, Cardiac Pacing, Artificial methods, Cardiac Pacing, Artificial statistics & numerical data, Diagnosis, Computer-Assisted methods, Electrocardiography statistics & numerical data, Tachycardia, Ventricular epidemiology, Tachycardia, Ventricular prevention & control, Therapy, Computer-Assisted methods
- Abstract
Background: The optimal programming of a pacemaker (PM) voltage output considers both efficiency (prolonging battery cell longevity) and patient safety (adequate safety margin). Currently, automatic capture (AC) algorithms are designed to ensure safe automatic stimulation threshold determination and pacing with a safety margin., Methods: The aims of this prospective observational study were (1) to evaluate, over a short-term follow-up, the extent of backup pacing in patients implanted with an AC-featured PM produced by Boston Scientific (Insignia) and a wide range of ventricular leads; (2) to identify patient- or lead-specific predictors of ventricular threshold increase or missed detection of the ventricular pacing threshold; and (3) to analyze day-to-day fluctuations in the ventricular pacing threshold and the relationship between their magnitude, the characteristics of patients, and the system implanted., Results: Five hundred and seventy-nine patients implanted with 89 different leads were followed up for a median of 2.1 months. Five hundred and thirty-six patients (92.5%) never experienced failure of automatic threshold testing; 571 (98.6%) did not experience permanent failure requiring continuous backup pacing at high energy. On multivariate analysis, none of the patient or lead characteristics predicted the occurrence of high-energy backup pacing during the study period. Day-to-day threshold fluctuations were associated only with higher thresholds (>1 V)., Conclusion: AC algorithm reliably measures ventricular pacing thresholds in most patients: in only 1.4% of patients the system is permanently unable to detect the ventricular threshold. Backup pacing is not dependent on lead or patient characteristics, including lead polarization, polarity, and maturation.
- Published
- 2008
- Full Text
- View/download PDF
47. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial.
- Author
-
Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, Di Giovanni N, Colletti A, Pensabene O, Lisi F, Vasquez L, Grammatico A, and Boriani G
- Subjects
- Aged, Aged, 80 and over, Arrhythmia, Sinus diagnosis, Arrhythmia, Sinus mortality, Atrial Fibrillation mortality, Cardiac Pacing, Artificial, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Electrocardiography, Female, Flecainide administration & dosage, Follow-Up Studies, Humans, Male, Probability, Propafenone administration & dosage, Prospective Studies, Reference Values, Risk Assessment, Single-Blind Method, Sotalol administration & dosage, Statistics, Nonparametric, Survival Rate, Treatment Outcome, Amiodarone administration & dosage, Anti-Arrhythmia Agents administration & dosage, Arrhythmia, Sinus therapy, Atrial Fibrillation drug therapy, Atrial Fibrillation prevention & control
- Abstract
Background: Rhythm control is an important goal in the treatment of recurrent atrial tachyarrhythmias (AT). The PITAGORA study was a randomized trial in patients paced for sinus node disease (SND), designed to test the noninferiority of class IC antiarrhythmic drugs (AADs) to amiodarone in terms of a primary end point composed of death, permanent AT, cardiovascular hospitalization, atrial cardioversion, or AAD change., Methods: Randomization was stratified to assign 2 patients to amiodarone and 2 patients to class IC AADs: propafenone or flecainide. One hundred seventy-six patients (46% men, 72 +/- 8 years) were enrolled. Device diagnostics continuously monitored AT recurrences and duration., Results: In a mean follow-up of 20 +/- 9 months, the primary end point occurred in 23 (30.7%) of 75 class IC patients and in 28 (40.0%) of 70 amiodarone patients. The absolute difference in the end point incidence (-9.3%; 95% CI between 3.7% and -22.3%) confirmed the noninferiority of class IC to amiodarone (P = .007). Kaplan-Meier 1-year freedom from AT episodes >10 minutes, 1 day, and 7 days was 40%, 73%, and 91% for amiodarone and 28%, 78%, and 86% for class IC AADs (P = nonsignificant)., Conclusions: In patients paced for SND and suffering from AT, class IC AADs proved not to be inferior to amiodarone in terms of the primary composite end point described or end points which were differently composed of mortality, efficacy, or AAD side effects. The AADs studied also showed similar results in terms of symptoms, quality of life, and freedom from AT recurrences.
- Published
- 2008
- Full Text
- View/download PDF
48. Results of the SCART study: selection of candidates for cardiac resynchronisation therapy.
- Author
-
Peraldo C, Achilli A, Orazi S, Bianchi S, Sassara M, Laurenzi F, Cesario A, Fratianni G, Lombardo E, Valsecchi S, Denaro A, and Puglisi A
- Subjects
- Aged, Echocardiography, Doppler, Female, Heart Failure complications, Humans, Male, Prospective Studies, Stroke Volume, Ventricular Dysfunction, Left complications, Ventricular Dysfunction, Left diagnostic imaging, Cardiac Pacing, Artificial, Heart Failure therapy, Patient Selection
- Abstract
Objective: To prospectively determine whether prespecified electrocardiographic, echocardiographic and tissue Doppler imaging (TDI) selection criteria may predict a positive response to cardiac resynchronisation therapy (CRT)., Methods: In this multicentre, prospective, non-randomised study, 96 heart failure patients with New York Heart Association class III-IV symptoms, an ejection fraction of < or =35%, and at least one marker of ventricular dyssynchrony according to prespecified electrocardiographic, echocardiographic or TDI criteria were enrolled. The primary endpoint was an improvement in the clinical composite score at 6 months., Results: At enrolment, 70 patients fulfilled the electrocardiographic criterion (QRS duration > or =150 ms), 77 patients showed echocardiographic signs of dyssynchrony, and 37 patients met the TDI dyssynchrony criteria. The overall responder rate was 78/96 (81%). In particular, the primary endpoint was reached in 68 patients who fulfilled the echocardiographic criteria as compared with 10 patients who did not (88 vs. 53%, P = 0.001). The patients who met the echocardiographic criteria showed a significant greater reduction in left ventricular end-systolic diameter (P = 0.029) and a higher improvement in quality of life (P = 0.017) than patients who did not. Neither electrocardiographic nor TDI criteria seemed to predict a positive response to CRT., Conclusions: In our patient population, mechanical indexes of dyssynchrony as assessed by echocardiography appeared to identify CRT responders. Although TDI is useful for evaluating ventricular dyssynchrony after CRT, the prespecified TDI inclusion criteria adopted in this investigation did not increase the number of CRT responders.
- Published
- 2007
- Full Text
- View/download PDF
49. Efficacy of cardiac resynchronization therapy in very old patients: the Insync/Insync ICD Italian Registry.
- Author
-
Achilli A, Turreni F, Gasparini M, Lunati M, Sassara M, Santini M, Landolina M, Padeletti L, Puglisi A, Bocchiardo M, Orazi S, Perego GB, Valsecchi S, and Denaro A
- Subjects
- Aged, Aged, 80 and over, Comorbidity, Female, Humans, Italy epidemiology, Longitudinal Studies, Male, Middle Aged, Prevalence, Risk Factors, Survival Analysis, Survival Rate, Cardiac Pacing, Artificial mortality, Heart Failure mortality, Heart Failure prevention & control, Registries statistics & numerical data, Risk Assessment methods, Ventricular Dysfunction, Left mortality, Ventricular Dysfunction, Left prevention & control
- Abstract
Aims: To assess the effects of cardiac resynchronization therapy (CRT) in > or =80-year-old patients vs. patients <80 years, in terms of clinical, functional, and echocardiographic parameters after 12 month of CRT, survival, and incidence of arrhythmic events., Methods and Results: The study population consisted of 1181 CRT patients (85 were > or =80 years old). They were enrolled in a national observational registry and underwent baseline evaluation and periodical follow-up visits. In the overall population, New York Heart Association class and ejection fraction (EF) improved and ventricular diameters decreased. Similar changes were observed in the two groups. In the study population, 157 patients died, 144 (13%) in the <80 years group and 13 (15%) in the > or =80 years group. There was a higher all-cause mortality (log-rank test, P = 0.015) among > or =80 years patients, with a trend towards higher sudden cardiac death (SCD) (P = 0.057), but similar non-SCD (P = 0.293). Using the combined endpoint of SCD or appropriate shock from a defibrillator for ventricular fibrillation, no significant differences resulted between groups (P = 0.455). In both groups, lower EF was associated with higher mortality., Conclusion: Cardiac resynchronization therapy demonstrated similar efficacy in patients aged > or =80 years and in those under 80, in terms of clinical and functional parameters and reverse remodelling. Similarly, CRT resulted in comparable effects on death for heart failure and on SCD.
- Published
- 2007
- Full Text
- View/download PDF
50. Cardioinhibitory carotid sinus hypersensitivity predicts an asystolic mechanism of spontaneous neurally mediated syncope.
- Author
-
Maggi R, Menozzi C, Brignole M, Podoleanu C, Iori M, Sutton R, Moya A, Giada F, Orazi S, and Grovale N
- Subjects
- Aged, Female, Humans, Male, Reproducibility of Results, Sensitivity and Specificity, Vasodilator Agents, Adenosine, Atrioventricular Node drug effects, Electrocardiography methods, Sick Sinus Syndrome diagnosis, Sinoatrial Node drug effects, Syncope, Vasovagal diagnosis
- Abstract
Aims: We correlated the finding of cardioinhibitory carotid sinus hypersensitivity (CSH) with that observed during a spontaneous syncopal relapse by means of an implantable loop recorder (ILR)., Methods and Results: We included 18 consecutive patients with suspected recurrent neurally mediated syncope and positive cardioinhibitory response during carotid sinus massage (max pause 5.5 +/- 1.6 s) who had subsequent documentation of a spontaneous syncope by means of an ILR. They were compared with a 2:1 age- and sex-matched group of 36 patients with a clinical diagnosis of recurrent neurally mediated syncope and negative response to carotid sinus massage, tilt testing and ATP test. Asystole >3 s was observed at the time of the spontaneous syncope in 16 (89%) of CSH patients and in 18 (50%) of the control group (P = 0.007). Sinus arrest was the most frequent finding among CSH patients but not among controls (72 vs. 28%, P = 0.003). After ILR documentation, 14 CSH patients with asystole received dual-chamber pacemaker implantation; during 35 +/- 22 months of follow-up, 2 syncopal episodes recurred in 2 patients (14%), and pre-syncope occurred in another 2 patients (14%). Syncope burden decreased from 1.68 (95% confidence interval 1.66 - 1.70) episodes per patient per year before to 0.04 (0.038-0.042) after pacemaker implant (98% relative risk reduction)., Conclusions: In patients with suspected neurally mediated syncope, the finding of cardioinhibitory CSH predicts an asystolic mechanism at the time of spontaneous syncope and, consequently, suggests a possible benefit of cardiac pacing therapy.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.